Carboxamide compound

Abstract

NOT VISIBLE DUE TO STATUS OF PATENT

Description

Carboxamide Compounds

[0001] The present invention relates to carboxamide compounds and pharmaceutical compositions containing the same, particularly to carboxamide compounds and pharmaceutical compositions containing the same for the prevention, alleviation, and / or treatment of diseases whose symptoms are improved by antagonizing lysophosphatidic acid (LPA) receptors.

[0002] Lysophosphatidic acid (LPA) is an endogenous physiologically active phospholipid. Six subtypes of LPA receptors, G protein-coupled receptors LPA1 to LPA6, are known. LPA binds to these receptors and transmits signals intracellularly, regulating cell proliferation, differentiation, survival, migration, adhesion, invasion, and morphogenesis. LPA is also known to be involved in fibrotic diseases in various organs. Regarding the lungs, elevated LPA concentrations have been reported in the alveolar lavage fluid of patients with idiopathic pulmonary fibrosis (IPF). Furthermore, LPA1 receptors are more highly expressed in patient-derived fibroblasts than other subtypes, and LPA induces fibroblast migration via the LPA1 receptor. Furthermore, elevated LPA concentrations in the alveolar lavage fluid of bleomycin-induced pulmonary fibrosis mouse models have been shown, and fibrosis is suppressed by LPA1 receptor deficiency or administration of an LPA1 receptor antagonist (see Non-Patent Documents 1 and 2). Recently, it has been reported that the LPA1 receptor antagonist BMS-986020 significantly reduced the rate of decline in forced vital capacity in patients with IPF in a 26-week clinical trial (see Non-Patent Document 3). Regarding skin, serum LPA concentrations are elevated in patients with systemic sclerosis, and in bleomycin-induced scleroderma model mice, LPA1 receptor deficiency or administration of an LPA1 receptor antagonist has been reported to suppress skin fibrosis (see Non-Patent Documents 4-6). Regarding the liver, LPA is known to promote the proliferation of stellate cells, which play an important role in the process of liver fibrosis, and the migration of myofibroblasts (see Non-Patent Documents 7 and 8). Furthermore, it has been reported that LPA concentrations are elevated in the plasma of patients with chronic hepatitis C, and that there is a correlation between LPA concentration and the degree of liver fibrosis (see Non-Patent Document 9). Regarding the kidney, it has been reported that LPA production and LPA1 receptor expression are enhanced in unilateral ureteral ligation mice, an animal model of renal fibrosis, and that renal fibrosis is suppressed by LPA1 receptor deficiency or administration of an LPA1 receptor antagonist (see non-patent literature 10 and 11).

[0003] LPA is also known to be involved in acute and chronic pain. LPA1 receptors are expressed in the peripheral and central nervous systems, and have been reported to be particularly abundant in Schwann cells and satellite glial cells in the peripheral nervous system (see Non-Patent Documents 12 and 13). In various pain model animals, such as a partial sciatic nerve injury model, LPA1 receptor deficiency, antisense oligonucleotide administration, or LPA1 receptor antagonist administration suppressed allodynia and hyperalgesia, demonstrating the involvement of LPA and LPA1 receptors in acute and chronic pain (see Non-Patent Documents 13-17). It has also been reported that intrathecal administration of LPA in mice induces allodynia and demyelination of spinal nerves, and that LPA1 receptor deficiency suppresses these effects (see Non-Patent Document 14). Additionally, LPA inhibition and administration of LPA1 receptor antagonists have been reported to alleviate pain symptoms and pathologies associated with demyelination in spinal cord injury and spinal canal stenosis model animals (see Non-Patent Documents 18-21). Furthermore, LPA concentrations are elevated in the cerebrospinal fluid of patients with pain associated with various diseases, and are correlated with the severity of the pain (see Non-Patent Documents 22 and 23). LPA is also known to be involved in immune and inflammatory diseases. It has been reported that LPA enhances the migration of human monocytic cells and is involved in the proliferation and infiltration of T cells. Synovial cells in rheumatoid arthritis patients express LPA receptors, which induce migration or the production of IL-6 and IL-8 upon stimulation with LPA. Furthermore, macrophages in multiple sclerosis patients express increased LPA1 receptors, which, upon stimulation with LPA, transform into M1-type macrophages, which produce inflammatory cytokines. These effects have been reported to be inhibited by LPA receptor antagonists (see Non-Patent Documents 24-27). Other reports include that LPA is involved in urinary system diseases by contracting excised urethral and prostate specimens and increasing intraurethral pressure (see Patent Document 1), and that LPA is involved in cancer-related diseases by promoting the invasion of cancer cells, the proliferation of ovarian cancer cells, or the proliferation of prostate cancer cells (see Non-Patent Documents 28-30).

[0004] For these reasons, drugs that antagonize LPA receptors, particularly LPA1 receptors, are considered to be useful for the prevention and / or treatment of diseases accompanied by fibrosis, central and peripheral nervous system diseases, immune and inflammatory diseases, urinary system diseases, cancer-related diseases, etc. To date, carboxamide compounds have been disclosed in Patent Documents 2-5 and Non-Patent Documents 31-32 as compounds having LPA receptor antagonistic activity, but all of them have structures different from the compound of the present invention.

[0005] International Publication No. WO2002 / 062389 International Publication No. WO2019 / 234115 International Publication No. WO2020 / 254408 International Publication No. WO2021 / 110805 International Publication No. WO2023 / 014907

[0006] Nature Medicine,14(2008)45-54.British Journal of Pharmacology,160(2010)1699-1713.Chest,154(2018)1061-1069.International Journal of Medical Sciences,6(2009)168-76.Arthritis & Rheumatism,63(2011)1405-1415.Experimental Dermatology,24(2015)698-702.Biochemical and Biophysical Research Communications,248(1998)436-440.Journal of Biomedical Science,10(2003)352-358.Journal of Clinical Gastroenterology,41(2007)616-623.Journal of the American Society of Nephrology,18(2007)3110-3118.The Journal of Pharmacology and Experimental Therapeutics,336(2011)693-700.Glia,61(2013)2009-2022.FASEB Journal,36(2022)e22236.Nature Medicine,10(2004)712-718.Molecular Pain,10(2014)71.Neurobiology of Pain, 1(2017)16-25.Cells,9(2020)1906.The American Journal of Pathology,181(2012)978-992.The Journal of Neuroscience,35(2015)10224-10235.Scientific Reports,9(2019)16578.Scientific Reports,11(2021)3984.PLoS ONE,13(2018)e0207310.Scientific Reports,9(2019)9144.Journal of Biological Chemistry,270 (1995) 25549-25556. Biochimica et Biophysica Acta, 1582 (2002) 168-174. Molecular Pharmacology, 73 (2008) 587-600. Molecular Neurobiology, 58 (2021) 470-482. Biochemical and Biophysical Research Communications, 193 (1993) 497-503. Biochemical Journal, 309 (1995) 933-940. The Journal of Urology, 163 (2000) 1027. Journal of Medicinal Chemistry, 67 (2024) 2379. Journal of Medicinal Chemistry, 67 (2024) 2397. ,

[0007] The present invention provides novel compounds and pharmaceutical compositions containing the same that are useful for the prevention, alleviation, and / or treatment of diseases whose symptoms are improved by antagonizing LPA receptors.

[0008] As a result of extensive research into compounds having LPA receptor antagonistic activity, the present inventors have found that the compound of the present invention, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, has excellent LPA receptor antagonistic activity and is useful for the prevention, alleviation, and / or treatment of diseases whose symptoms are improved by antagonizing the LPA receptor, and have completed the present invention.

[0009] The present invention provides the following [1] to

[13] . [1] A compound represented by the following general formula (I): wherein ring A is a benzene ring or a 5- to 6-membered aromatic heterocycle; １ is C １ -C ６ Alkyl group or C ３ -C ６ is a cycloalkyl group, R ２ is a hydrogen atom or a halogen atom, R ３ is a hydrogen atom or C １ -C ６ is an alkyl group, R ４is a hydrogen atom, a halogen atom, or C optionally substituted with 1 to 5 halogen atoms. １ -C ６ C optionally substituted with an alkyl group or 1 to 5 halogen atoms １ -C ６ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ represents a hydrogen atom, a halogen atom, or C １ -C ６ alkyl group, or C １ -C ６ an alkoxy group, and G is a hydrogen atom, a formyl group, or C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q1 ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 includes a halogen atom, a hydroxy group, and C which may be substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ RＮ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, wherein G is optionally substituted by 1 to 5 substituents independently selected from the group Q1. ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group or a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from the group Q1, wherein two adjacent carbon atoms on the ring of the cycloalkyl group, the aryl group or the heteroaryl group are each substituted with a carboxy group and one hydroxy group; １ -C ６ When substituted with an alkyl group, the C substituted with the carboxy group and one hydroxy group １ -C ６ The alkyl groups may be taken together with the carbon atoms to which they are attached to form a lactone ring, R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C１ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ are each independently C １ -C ６ Group Q2 is a C alkyl group optionally substituted with 1 to 5 substituents independently selected from a halogen atom, a hydroxy group, an oxo group, and Group Q3. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ C optionally substituted with 1 to 5 substituents independently selected from an acyl group, a carboxy group, and group Q3 １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ７ R Ｎ８ and 3- to 12-membered non-aromatic heterocyclyl groups, R Ｎ７ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ８ is a hydrogen atom or C １ -C ６ Group Q3 is a halogen atom, OR Q３ , C２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０ , and C ６ -C １０ is a group consisting of aryl groups, R Q３ is a hydrogen atom, C １ -C ６ C optionally substituted with an alkyl group, one amino group ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｇ１ , R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted by 1 to 5 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the group Q4 ２ -C １０ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ alkylamino-carbonyl group, and the group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C ６R is a group consisting of 3- to 12-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ is an alkyl group, １ is a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl group, C substituted with one hydroxy group １ -C ６ C optionally substituted with an alkyl group and 1 to 5 halogen atoms １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ５ , R Ｇ６ , R Ｇ７ , and R Ｇ１１ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６L is a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with an alkyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ an alkyl group, an alkyl group substituted with one hydroxy group, a C group optionally substituted with 1 to 5 halogen atoms, １ -C ６ Alkoxy groups, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ８ and R Ｇ９ are each independently a hydrogen atom, a halogen atom, or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group may be a halogen atom, a hydroxyl group, or a C １ -C ６ R is optionally substituted with 1 to 5 substituents independently selected from alkoxy groups; Ｇ１０ is a hydroxy group, C ２ -C ６ Alkynyl group, C ２ -C ６ alkenyl group, C optionally substituted with 1 to 3 halogen atoms １ -C ６ Alkoxy group, carboxy group, C １ -C ６Alkoxy-carbonyl group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, or a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ and m and n are each independently an integer of 1 or 2.] or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. [2] A compound represented by the following general formula (I-a) or (I-b): [In the formula, R １ is C １ -C ６ Alkyl group or C ３ -C ６ is a cycloalkyl group, R ２ is a hydrogen atom or a halogen atom, R ３ is a hydrogen atom or C １ -C ６ is an alkyl group, R ４ is a halogen atom, C １ -C ６ alkyl group, or C １ -C ６ is an alkoxy group, and X is CR５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, a formyl group, C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ a cycloalkyl group, a phenyl group which may be substituted by 1 to 3 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 4- to 12-membered non-aromatic heterocyclyl group which may be substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 includes a halogen atom, a hydroxy group, and C which may be substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ are each independently C １ -C ６ Group Q2 is an oxo group, a C alkyl group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ Alkyl group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ The group Q3 is a group consisting of a halogen atom, an OR Q３ , C ２ -C ６ Acyl group, carboxy group, C１ -C ６ Alkoxy-carbonyl groups, cyano groups, and NR Ｎ９ R Ｎ１０ R Q３ is a hydrogen atom, C １ -C ６ C optionally substituted with an alkyl group, one amino group ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q4 ２ -C １０ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted by 1 to 2 substituents independently selected from the group Q4 １ -C ６ Alkyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C６ R is a group consisting of 4- to 6-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ is an alkyl group, １ is a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ C substituted with an alkyl group and one hydroxy group １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, a carboxy group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６ a 4- to 6-membered non-aromatic heterocyclyl group optionally substituted with an alkyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ Alkyl group, alkyl group substituted with one hydroxy group, C １ -C ６ Alkoxy groups, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ８ and R Ｇ９ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group may be a hydroxy group, or a C １ -C ６ R is optionally substituted with 1 to 5 substituents independently selected from alkoxy groups; Ｇ１０ is a hydroxy group, C ２ -C ６ an alkynyl group, C optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２-C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, or a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ [3] The compound according to [1], or a deuterated product thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group, and m and n are each independently an integer of 1 or 2. Ｎ１ is a hydrogen atom, or C １ -C ６ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ５ , and R Ｎ６ is a hydrogen atom, and Group Q2 is an oxo group, C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ Alkyl groups, and C ２ -C ６ R is a group consisting of acyl groups; Ｎ９ , and R Ｎ１０ is a hydrogen atom, and R Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ６C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ is an acyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ The group Q4 is a hydroxy group, C １ -C ６ R is a group consisting of an alkoxy group and an amino group; Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or a 4- to 6-membered non-aromatic heterocyclyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl groups, alkyl groups substituted with one hydroxy group, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ The alkyl groups together with the carbon atoms to which they are attached form C ３ -C ６ A cycloalkane ring may be formed, and R Ｎ１３ is a hydrogen atom, C ２ -C ６Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ [4] The compound according to [2], or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following general formula (I-c): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ４ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ a cycloalkyl group, a phenyl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group which may be substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 includes a halogen atom, a hydroxy group, and C which may be substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ４ Alkoxy group, carboxy group, C １-C ４ Alkoxy-carbonyl group, C １ -C ４ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ are each independently C １ -C ４ Group Q2 is an alkyl group, and Group Q3 is an oxo group and a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ Group Q3 is a group consisting of a halogen atom, OR Q３ and a carboxy group, R Q３is a hydrogen atom, a C optionally substituted with one amino group ２ -C ６ Acyl group, or C １ -C ４ is an alkoxy-carbonyl group, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ is an acyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The group Q4 is a hydroxy group and C １ -C ４ L is a group consisting of alkoxy groups; １ is 1 to 3 C １ -C ４ A linear C optionally substituted with an alkyl group １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C substituted with a hydroxy group and 1 to 3 fluorine atoms. １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group;１ -C ４ is an alkyl group, R Ｇ１０ is a C optionally substituted with a hydroxy group or 1 to 3 fluorine atoms. １ -C ４ Alkoxy group, carboxy group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１３ is a hydrogen atom, C ２ -C ６ Acyl group, C １ -C ４ an alkoxy-carbonyl group, or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ４ [5] The compound according to [1], or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein in formula (I-c), R １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom or a methoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a fluorine atom, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４an alkyl group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): Group Q1 is a C optionally substituted by a halogen atom or one hydroxy group １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom, or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ４Group Q2 is an alkyl group optionally substituted with an oxo group and one hydroxy group; １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ C optionally substituted with a hydroxy group, 1 to 3 fluorine atoms １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ [6] The compound according to [4], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following general formula (I-d): [7] The compound according to [5], represented by the formula (I-d), or a pharmaceutically acceptable salt thereof: [wherein the symbols are as defined in [5]] １ But C １ -C ４ is an alkyl group, R３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom, and R ５ is a hydrogen atom or a fluorine atom, G is a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulas (II-1), (II-3), or (II-8): The group Q1 is C optionally substituted with one hydroxy group １ -C ４ Group Q2 is a group consisting of an alkyl group and a carboxy group, and Group Q3 is a group consisting of an oxo group and a C group optionally substituted with one hydroxy group. １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with one substituent selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a hydroxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ [8] The compound according to [6], or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following general formula (I-e): [9] The compound according to [5], represented by the formula (I-e): [wherein the symbols are as defined in [5]], or a pharmaceutically acceptable salt thereof. １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom or a methoxy group, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４ an alkyl group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): Group Q1 is a C optionally substituted by a halogen atom or one hydroxy group １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ４ The group Q2 is an oxo group and C １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R may be substituted with 1 to 3 substituents selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ is a hydrogen atom, and R Ｇ１０ C optionally substituted with a hydroxy group or 1 to 3 fluorine atoms １ -C ４

[0023] The compound according to [8], or a pharmaceutically acceptable salt thereof, wherein N-(2-carbamoyl-4-chlorophenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(2-carbamoyl-4-chloro-5-fluorophenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-chloro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-bromo-2-carbamoylphenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-bromo-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(2-carbamoyl-5-fluoro-4-methylphenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(5-fluoro-4-methyl-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide)-N-methylisonicotinamide;tert-Butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxyacetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N; ３-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide; 1-carbamothioyl-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N'-cyanocarbamimidoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid; methyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxetan-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(trans-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cis-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; Methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate;6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; N-(4-chloro-5-fluoro-2-((methyl-d3)carbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4,5-difluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4,5-difluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4,5-difluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((6-bromo-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-bromo-5-(3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-bromo-5-(3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-fluoro-6-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-fluoro-6-isopropylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-fluoro-6-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-ethylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-ethylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-ethylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-propylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-propylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-propylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isobutylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isobutylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isobutylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-cyclopentylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-cyclopentylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-cyclopentylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(3-isopropylthiophen-2-yl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(3-isopropylthiophen-2-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(3-isopropylthiophen-2-yl)-1-sulfamoylazetidine-3-carboxamide; 3-(5-chloro-3-isopropylthiophen-2-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-chloro-5-(3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-hydroxyacetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-hydroxypropanoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N; ３-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide; 2-chloro-5-(1-(N'-cyanocarbamimidoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid; 2-chloro-5-(1-(3-hydroxy-3-methylbutanoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-carbamothioyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)acetate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)acetic acid; ethyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)butanoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)butanoic acid;Methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoate 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoic acid; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pentanoate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pentanoic acid; Methyl 1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclobutane-1-carboxylate; 1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclobutane-1-carboxylic acid; methyl 2-(1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclopropyl)acetate; 2-(1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclopropyl)acetic acid; methyl 4-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 4-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid;Methyl 3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid; Methyl 2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid; Methyl 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)nicotinate; 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)nicotinic acid; methyl 5-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)picolinate; 5-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)picolinic acid; methyl 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)pyridazine-3-carboxylate; 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)pyridazine-3-carboxylic acid;tert-butyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutane-1-carboxylate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutane-1-carboxylic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-methylazetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(tetrahydropyran-4-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-fluoro-3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-difluoro-3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 3-hydroxypropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-hydroxypropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-hydroxyethyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,4-dihydroxybutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(trans-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(cis-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; ethyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-5-carboxylic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-5-methylnicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-5-methylnicotinic acid; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)isonicotinate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)isonicotinic acid; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinic acid; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylnicotinate;6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylnicotinic acid; methyl 2-amino-6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 2-amino-6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-methylnicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-methylnicotinic acid; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methoxynicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methoxynicotinic acid; methyl 2-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 2-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; 2-chloro-5-(3-(2-isopropylphenyl)-1-(thiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylate;6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylic acid; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylic acid; ethyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylic acid; methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylic acid; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-4-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-4-carboxylic acid; Ethyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,3,4-thiadiazole-2-carboxylate;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide; Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-5-carboxylic acid; Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-5-carboxylic acid; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-4-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-4-carboxylic acid; ethyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylic acid; methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate;6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylate; 6-(3((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylic acid; ethyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylate; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylic acid; ethyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,3,4-thiadiazole-2-carboxylate; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-cyanopyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-(6-acetylpyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-(methylsulfonyl)pyridazin-3-yl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-sulfamoylpyridazin-3-yl)azetidine-3-carboxamide; 2-chloro-5-(1-(6-chloropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-chloro-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-methyl-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-(5-amino-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-methyl-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid;Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluoropicolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluoropicolinic acid; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylpicolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylpicolinate; Methyl 6-chloro-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 6-chloro-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid; methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-methylpicolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-methylpicolinate; methyl 3-amino-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 3-amino-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid; methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-2-carboxylate;5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-2-carboxylic acid; methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid; tert-butyl (6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazin-3-yl)carbamate; 1-(6-aminopyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxamide; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-methylpyridazine-3-carboxamide; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N,N-dimethylpyridazine-3-carboxamide; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,3,4-thiadiazole-2-carboxamide;2-chloro-5-(1-(5-cyano-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-(hydroxymethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(5-(hydroxymethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-(1-hydroxyethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(4-(hydroxymethyl)oxazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(6-(hydroxymethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-(hydroxymethyl)-1,2,4-thiadiazol-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; Ethyl 2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-4-carboxylate;2-chloro-5-(1-(4-(hydroxymethyl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-5-carboxylate; 2-chloro-5-(1-(5-(hydroxymethyl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(hydroxymethyl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 1-(6-(aminomethyl)pyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(3-(2-hydroxypropan-2-yl)-1,2,4-thiadiazol-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(6-(2-hydroxypropan-2-yl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(4-(2-hydroxypropan-2-yl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-cyanopropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cyanomethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-cyanoethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((1-cyanocyclopropyl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxyethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-methoxyethyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(3-methoxypropyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(prop-2-yn-1-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxetan-2-ylmethyl)azetidine-3-carboxamide;1-((1,3-dioxolan-2-yl)methyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-cyano-2-hydroxyethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((3-(hydroxymethyl)oxetan-3-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-(2-(1H-tetrazol-5-yl)ethyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-((1H-tetrazol-5-yl)methyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-methoxypropyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-cyanoethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; Methyl 3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoate; 3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoic acid; 2-chloro-5-(1-(2-hydroxyethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-benzyl-3-(2-isopropylphenyl)azetidine-3-carboxamido)-2-chloro-N-methylisonicotinamide;2-chloro-5-(3-(2-isopropylphenyl)-1-(pyridin-4-ylmethyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(pyridin-3-ylmethyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-cyano-3-hydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(1-cyano-3-hydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-cyano-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxiran-2-ylmethyl)azetidine-3-carboxamide; 1-(3-amino-2-hydroxypropyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,3-dihydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (S)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide (S)—N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,3-dihydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2,2,2-trifluoroethyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-difluoroethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cis-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(trans-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3,3-difluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1,1-dioxidothietan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-dioxido-2-thiaspiro[3.3]heptan-6-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(trans-3-(methylsulfonyl)cyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(cis-3-(methylsulfonyl)cyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-(methylsulfonyl)butyl)azetidine-3-carboxamide; 2-chloro-5-(1-(3-fluoropropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;(R)-2-chloro-5-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (R)-2-chloro-5-(1-(2,3-dihydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(3-(methylsulfonyl)propyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-fluoroethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((3-(cyanomethyl)oxetan-3-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,2-dimethyl-1,3-dioxan-5-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-hydroxy-2-(hydroxymethyl)propyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-fluoropropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 3-fluoropropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxetan-3-ylmethyl)azetidine-3-carboxamide;Oxetan-3-ylmethyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-difluoropropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2,2-difluoropropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-chloro-5-(1-(3-cyanopropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 3-cyanopropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-fluoro-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3,3-difluoro-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (S)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,3-dihydroxy-3-methylbutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;2-chloro-5-(1-(3-fluoro-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-hydroxy-2-methylpropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbutanoate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbutanoic acid; ethyl 2-(1-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutyl)acetate; 2-(1-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutyl)acetic acid; ethyl 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxetan-3-yl)acetate; 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxetan-3-yl)acetic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-(cyanomethyl)oxetan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)-3,3,3-trifluoropropanoic acid;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-(methylsulfonyl)ethyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-(2-hydroxyethyl)oxetan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-hydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methoxypropan-2-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-cyclobutyl-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(trans-3-methoxycyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(cis-3-methoxycyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(trans-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cis-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(tetrahydrofuran-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(tetrahydropyran-3-yl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1,1-dioxidetetrahydrothiopyran-4-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-oxaspiro[3.3]heptan-6-yl)azetidine-3-carboxamide; 1'-acetyl-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-[1,3'-biazetidine]-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1,3-dihydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-cyanooxetan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-cyclobutyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(trans-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(cis-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-oxaspiro[3.3]heptan-6-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl ((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)carbamate;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-(2-hydroxyethyl)sulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-(2,3-dihydroxypropyl)sulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; tert-butyl ((3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)carbamate; 2-chloro-5-(3-(2-isopropylphenyl)-1-(N-methylsulfamoyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-propionylsulfamoyl)azetidine-3-carboxamide; 1-(N-acetylsulfamoyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-(N-butyrylsulfamoyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-isobutyrylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-pentanoylsulfamoyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-hexanoylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-octanoylsulfamoyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-(2-methoxyacetyl)sulfamoyl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(N-propionylsulfamoyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(N-pentanoylsulfamoyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(N-heptanoylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl (2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine)-1-sulfonamido)-2-oxoethyl)carbamate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-glycylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(methylcarbamothioyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(methylcarbamothioyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2-hydroxyethyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;(R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,3-dihydroxypropyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-((2-hydroxyethyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-propionylazetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-acetyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 5-(1-butyryl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(1-formyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-ethanethioyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(methylsulfonyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; ethyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; Propyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-methoxy-2,2-dimethyl-3-oxopropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate;3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)-2,2-dimethylpropanoic acid; (2,2-dimethyl-1,3-dioxan-5-yl)methyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-hydroxy-2-(hydroxymethyl)propyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-cyanoethyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-methoxy-2,2-dimethyl-3-oxopropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-((3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)-2,2-dimethylpropanoic acid; 3-hydroxy-3-methylbutyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-Methoxyethyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-Methoxypropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-Hydroxy-2-methylpropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate;O-methyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbothioate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-chloropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-(2-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-(3-hydroxypropyl)-6-oxo-1,6-dihydropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;1-(1-(2-aminoethyl)-6-oxo-1,6-dihydropyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide; tert-butyl 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-oxopyridazin-1(6H)-yl)acetate; 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-oxopyridazin-1(6H)-yl)acetic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrooxazol-2-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrooxazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrothiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrothiazol-2-yl)azetidine-3-carboxamide; tert-butyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-oxo-4,5-dihydro-1H-imidazole-1-carboxylate;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide; tert-butyl 2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-oxo-4,5-dihydro-1H-imidazole-1-carboxylate; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-methyl-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-methyl-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(4-(2-hydroxyethyl)-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-ethyl-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-oxo-4-(2-oxopropyl)-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; Ethyl (3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonothioyl)carbamate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-((methylcarbamoyl)carbamothioyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-methyl-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-((methylcarbamoyl)carbamothioyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-methyl-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide;tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)pyrrolidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)pyrrolidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylpyrrolidine-3-carboxamide; tert-butyl 4-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-4-(2-isopropylphenyl)piperidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-4-(2-isopropylphenyl)piperidine-4-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-4-(2-isopropylphenyl)-1-sulfamoylpiperidine-4-carboxamide; tert-butyl 4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidine-1-carboxylate; 2-chloro-5-(4-(2-isopropylphenyl)piperidine-4-carboxamide)-N-methylisonicotinamide; methyl 4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidine-1-carboxylate; Methyl 4-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 4-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; Methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylamino)nicotinate;6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylamino)nicotinic acid; methyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylate; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylic acid; 2-chloro-5-(3-(2-isopropylphenyl)-1-(6-(methylsulfonyl)pyridazin-3-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-(methylsulfonyl)pyridin-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-sulfamoylpyridin-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbenzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylbenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylbenzoic acid; methyl 3-chloro-4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate;3-chloro-4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluorobenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluorobenzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methoxybenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methoxybenzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(trifluoromethyl)benzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(trifluoromethyl)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylsulfonyl)benzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylsulfonyl)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(difluoromethoxy)benzoate;4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(difluoromethoxy)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3,5-difluorobenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3,5-difluorobenzoic acid; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-oxo-1,3-dihydroisobenzofuran-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(hydroxymethyl)benzoic acid; ethyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 5-(1-(4-carbamoyl-3-fluorophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-3-fluorophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-cyanophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxamide; 5-(1-(4-carbamoylphenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinate; 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinic acid; 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinamide; 2-chloro-5-(1-(5-(hydroxymethyl)pyrazin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-(4-(1H-tetrazol-5-yl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; Methyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid; 2-chloro-5-(1-(6-(hydroxymethyl)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1H-imidazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1H-imidazole-5-carboxylic acid; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-5-carboxylic acid; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-4-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-4-carboxylic acid; methyl 4-(3-((6-bromo-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 4-(3-((6-bromo-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid; methyl 4-(3-(2-isopropylphenyl)-3-((6-methoxy-2-(methylcarbamoyl)pyridin-3-yl)carbamoyl)azetidin-1-yl)benzoate;4-(3-(2-isopropylphenyl)-3-((6-methoxy-2-(methylcarbamoyl)pyridin-3-yl)carbamoyl)azetidin-1-yl)benzoic acid; methyl 6-(4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidin-1-yl)nicotinate; 6-(4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidin-1-yl)nicotinic acid; 2-chloro-5-(1-(3-ethoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-(trifluoromethoxy)propyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-(difluoromethoxy)propyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3,3-difluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(cis-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(trans-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-((3-(methoxymethyl)oxetan-3-yl)methyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (R)-2-chloro-5-(1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (S)-2-chloro-5-(1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(2-hydroxy-2-(1-hydroxycyclobutyl)ethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-(2,5-dioxopyrrolidin-1-yl)-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-ethoxy-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2,3-dihydroxy-3-methylbutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-((3-hydroxytetrahydrofuran-3-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-hydroxy-4-methoxybutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(1,3-dimethoxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-methoxybutan-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-(methylamino)ethyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-(N-methylacetamido)ethyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-(N-methylmethylsulfonamido)ethyl)azetidine-3-carboxamido)-N-methylisonicotinamide;Methyl (2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)ethyl)(methyl)carbamate; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-((methylsulfonyl)carbamoyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-((ethylsulfonyl)carbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(sulfamoylcarbamoyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-((N,N-dimethylsulfamoyl)carbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl acetate; (5-(3-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl propionate; (5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl methyl carbonate; (5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl L-valinate; 2-chloro-5-(1-(2-(hydroxymethyl)pyrimidin-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(5-(hydroxymethyl)pyrimidin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(5-methyl-1,1-dioxide-1,2,5-thiadiazolidine-2-carbonyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(6-methyl-1,1-dioxide-1,2,6-thiadiazinane-2-carbonyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(N-methylsulfamoylcarbamoyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(N,N-dimethylsulfamoyl)(methyl)carbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 6-(3-(1-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-(N,N-dimethylsulfamoyl)nicotinamide; 5-(3-(1-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-(N,N-dimethylsulfamoyl)picolinamide; 6-(3-(1-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-(N,N-dimethylsulfamoyl)pyridazine-3-carboxamide; 2-chloro-5-(1-(3-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(diethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(6-(dimethylphosphoryl)pyridin-3-yl)3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (R)-3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-hydroxypropyl acetate; (R)-1-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-hydroxypropan-2-yl acetate; (R)-3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propane-1,2-diyl diacetate; 2-chloro-5-(1-(5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-2-fluorophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-chloro-4-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-2-methylphenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-3-methylphenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-(dimethylphosphoryl)pyrimidin-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;tert-butyl (2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-5-(dimethylphosphoryl)pyridin-4-yl)carbamate; 5-(1-(4-amino-5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(1-(5-(dimethylphosphoryl)-4-(methylamino)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-(3-amino-4-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 5-(1-(6-amino-5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoronicotinamide; Methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoropyridazine-3-carboxylate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoropyridazine-3-carboxylic acid; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoropyridazine-3-carboxamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-3-(methylamino)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;and 2-chloro-5-(1-(5-(dimethylphosphoryl)-6-(methylamino)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof.

[11] A pharmaceutical composition comprising the compound according to any one of [1] to

[10] , or a deuterated form thereof, or a pharmaceutically acceptable salt thereof.

[12] The pharmaceutical composition according to

[11] , for preventing, alleviating, and / or treating a disease whose symptoms are improved by antagonizing a lysophosphatidic acid receptor.

[13] The pharmaceutical composition according to

[12] , wherein the disease whose symptoms are improved by antagonizing a lysophosphatidic acid receptor is pain or fibrosis.;

[0010] The compound represented by general formula (I) of the present invention, its deuterated derivative, or a pharmaceutically acceptable salt thereof has an LPA receptor antagonistic activity, and is therefore useful as a preventive, alleviating, and / or therapeutic agent for various diseases whose symptoms are improved by antagonizing LPA receptors, such as pain or fibrosis.

[0011] Embodiments of the present invention are described below. In this specification, "a compound represented by general formula (I)" and the like are also referred to as "compound (I)" and the like for convenience. The various substituents defined or exemplified below can be arbitrarily selected and combined. Furthermore, embodiments in which the respective embodiments defined below are arbitrarily selected and combined are also encompassed by the present invention.

[0012] The definitions of the terms used in this specification are as follows.

[0013] As used herein, the term "halogen atom" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.

[0014] When a substituent is substituted with two or more halogen atoms or substituents, the halogen atoms or substituents may be the same or different.

[0015] "C" as described herein Ｘ -C Ｙ " means that the number of carbon atoms is X to Y. For example, "C １ -C ６ " means that the number of carbon atoms is 1 to 6.

[0016] The term "alkyl group" used herein refers to a group having 1 to 6 carbon atoms (C １ -C ６ ), for example, a carbon number of 1 to 4 (C １ -C ４ ) and includes, for example, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, isobutyl, n-pentyl, n-hexyl, and various branched isomers thereof.

[0017] The term "alkenyl group" as used herein refers to an alkenyl group having one carbon-carbon double bond and 2 to 6 carbon atoms (C ２ ~C ６ ), for example, a carbon number of 2 to 4 (C ２ ~C ４ ) and includes, for example, vinyl, propenyl, isopropenyl, butenyl, and various branched isomers thereof.

[0018] The term "alkynyl group" as used herein refers to an alkynyl group having 2 to 6 carbon atoms (C ２ ~C ６ ), for example, a carbon number of 2 to 4 (C ２ ~C ４ ) and includes, for example, ethynyl, 1-propynyl, 2-butynyl, 4-pentynyl, 5-hexynyl, and various branched chain isomers thereof.

[0019] As used herein, the term "acyl group" (which may also be referred to as "alkanoyl group") refers to a group in which a carbonyl group is bonded to the aforementioned straight-chain or branched-chain alkyl group, and examples thereof include an ethanoyl group (acetyl group), propanoyl group, isopropanoyl group, n-butanoyl group, tert-butanoyl group, isobutanoyl group, n-pentanoyl group, and various branched-chain isomers thereof.

[0020] The "alkyl-SO ２ The term "sulfonyl group" refers to a group in which a sulfonyl group is bonded to the linear or branched alkyl group, such as methyl-SO ２ group, ethyl-SO ２ group, propyl-SO ２ group, isopropyl-SO ２ group, n-butyl-SO ２ group, tert-butyl-SO ２ group, isobutyl-SO ２ Group, n-pentyl-SO ２ Group, n-hexyl-SO ２ groups, and various branched chain isomers thereof.

[0021] The term "alkoxy group" as used herein refers to a group in which an oxygen atom is bonded to the aforementioned straight-chain or branched-chain alkyl group, and examples thereof include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, a tert-butoxy group, an isobutoxy group, an n-pentoxy group, an n-hexoxy group, and various branched-chain isomers thereof.

[0022] The term "alkoxy-carbonyl group" used herein means a group in which a carbonyl group is bonded to the aforementioned straight-chain or branched-chain alkoxy group, and examples thereof include a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, a tert-butoxycarbonyl group, an isobutoxycarbonyl group, an n-pentoxycarbonyl group, an n-hexoxycarbonyl group, and various branched-chain isomers thereof.

[0023] As used herein, the term "alkylamino-carbonyl group" refers to a group in which an amino group and a carbonyl group are bonded to the aforementioned straight-chain or branched-chain alkyl group, and examples thereof include a methylamino-carbonyl group, an ethylamino-carbonyl group, a propylamino-carbonyl group, an isopropylamino-carbonyl group, an n-butylamino-carbonyl group, a tert-butylamino-carbonyl group, an isobutylamino-carbonyl group, an n-pentylamino-carbonyl group, an n-hexylamino-carbonyl group, and various branched-chain isomers thereof.

[0024] The term "acyloxy group" used herein refers to a group in which an oxygen atom is bonded to the aforementioned straight-chain or branched-chain acyl group, and examples thereof include an ethanoyloxy group (acetyloxy group), propanoyloxy group, isopropanoyloxy group, n-butanoyloxy group, tert-butanoyloxy group, isobutanoyloxy group, n-pentanoyloxy group, and various branched-chain isomers thereof.

[0025] The term "alkylene group" used herein refers to a divalent group obtained by removing any one hydrogen atom from the above-mentioned "alkyl group". Examples of the alkylene group include C １ -C ６ Alkylene group, C ２ -C ４ Alkylene group, C ２ -C ３ an alkylene group, and C １ -C ２ Examples thereof include alkylene groups, and specific examples thereof include methylene, ethylene, methylmethylene, trimethylene, ethylmethylene, dimethylmethylene, tetramethylene, pentamethylene, and hexamethylene groups.

[0026] The term "cycloalkyl group" as used herein refers to a group having 3 to 6 ring carbon atoms (C ３ -C ６ ) and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.

[0027] The "cycloalkane ring" described in this specification refers to a ring having 3 to 6 carbon atoms (C３ -C ６ ) and includes, for example, cyclopropane, cyclobutane, cyclopentane, and cyclohexane.

[0028] The term "non-aromatic heterocyclyl group" as used herein means a 3- to 8-membered monocyclic non-aromatic heterocyclic group or a 6- to 12-membered bicyclic non-aromatic heterocyclic group containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms, and examples thereof include oxiranyl groups, azetidinyl groups, oxetanyl groups, thietanyl groups, pyrrolidinyl groups, piperidinyl groups, piperidino groups, tetrahydrofuryl groups, dioxolanyl groups, tetrahydropyranyl groups, dioxanyl groups, tetrahydrofuryl groups, and tetrahydropyranyl groups. a tetrahydrothienyl group (i.e., a thiolanyl group), a tetrahydrothiopyranyl group, a piperazinyl group, a morpholinyl group, a morpholino group, a perhydroazepinyl group, a perhydroazocinyl group, a 6- to 12-membered azabicycloalkyl group (e.g., an azabicyclohexyl group, an azabicycloheptyl group, an azabicyclooctyl group, an azabicyclononyl group, an azabicyclodecyl group, an azabicycloundecyl group, or an azabicyclododecyl group), a 6- to 12-membered azabicycloalkenyl ... For example, azabicyclohexenyl group, azabicycloheptenyl group, azabicyclooctenyl group, azabicyclononenyl group, azabicyclodecenyl group, azabicycloundecenyl group, or azabicyclododecenyl group), 6- to 12-membered azaspiroalkyl group (for example, azaspirohexyl group, azaspiroheptyl group, azaspirooctyl group, azaspirononyl group, azaspirodecyl group, azaspiroundecyl group, or azaspirododecyl group), 6- to 12-membered oxaza ... Examples of such groups include pyroalkyl groups (e.g., oxaspiroheptyl, oxaspirooctyl, oxaspirononyl, or oxaspirodecyl groups), 6- to 12-membered thiaspiroalkyl groups (e.g., thiaspiroheptyl, thiaspirooctyl, thiaspirononyl, or thiaspirodecyl groups), dihydrooxazolyl groups, dihydrothiazolyl groups, dihydroimidazolyl groups, dihydropyridazinyl groups, tetrahydropyridazinyl groups, and dihydrothiadiazolyl groups.

[0029] The term "aryl group" used herein refers to an aryl group having 6 to 10 ring carbon atoms (C ６ -C １０ , i.e., 6 to 10-membered) monocyclic or bicyclic aromatic hydrocarbon groups, for example, monocyclic aryl groups such as a phenyl group; ring-constituting carbon atoms of 9 to 10 (C), which may be partially saturated, such as a naphthyl group, a tetrahydronaphthyl group, an indenyl group, and an indanyl group; ９ ~C １０ , i.e., 9- to 10-membered bicyclic aryl groups.

[0030] The term "heteroaryl group" as used herein means a 5- to 10-membered monocyclic or bicyclic aromatic heterocyclic group containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms, and examples thereof include a pyrrolyl group, a furyl group, a thienyl group, a pyrazolyl group, an imidazolyl group, a tetrazolyl group, an oxazolyl group, an isoxazolyl group, an oxadiazolyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a pyridyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, and a triazinyl group; an indolyl group, an indolinyl group, an isoindolinyl group, an indazolyl group, a tetrazolyl group, a 5- to 6-membered monocyclic heteroaryl group containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms; Examples of such heteroaryl groups include 8- to 10-membered bicyclic heteroaryl groups containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms, such as a tetrahydroindazolyl group, a benzofuranyl group, a dihydrobenzofuranyl group, a dihydroisobenzofuranyl group, a benzothiophenyl group, a dihydrobenzothiophenyl group, a dihydroisobenzothiophenyl group, a benzoxazolyl group, a dihydrobenzoxazolyl group, a benzothiazolyl group, a dihydrobenzothiazolyl group, a quinolyl group, a tetrahydroquinolyl group, an isoquinolyl group, a tetrahydroisoquinolyl group, a naphthyridinyl group, a tetrahydronaphthyridinyl group, a quinoxalinyl group, a tetrahydroquinoxalinyl group, a quinazolinyl group, and a benzotriazinyl group.

[0031] The "5- to 6-membered aromatic heterocycle" as used herein means a 5- to 6-membered monocyclic aromatic heterocycle containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms, and examples thereof include aromatic heterocycles such as pyrrole, furan, thiophene, pyrazole, imidazole, tetrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine, and triazine.

[0032] As used herein, "R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ The term "may form an alkylene group" refers to the Ｎ３ R Ｎ４ but (R Ｎ４ and R Ｎ１５ Together they form C ２ forming an alkylene group), or (R Ｎ４ and R Ｎ１５ Together they form C ３ This means that the group may form a structure represented by the following formula (wherein the group forms an alkylene group):

[0033] The present invention relates to a compound in which "G is optionally substituted with 1 to 5 substituents independently selected from the group Q1". ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group or a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from the group Q1, wherein two adjacent carbon atoms on the ring of the cycloalkyl group, the aryl group or the heteroaryl group are each substituted with a carboxy group and one hydroxy group; １ -C ６ When substituted with an alkyl group, the C substituted with the carboxy group and one hydroxy group１ -C ６ The phrase "the alkyl groups may form a lactone ring together with the carbon atoms to which they are attached" means that, for example, when G is a phenyl group in which the two adjacent carbon atoms are substituted with a carboxy group and a hydroxymethyl group, respectively, the structure shown below may be formed.

[0034] The following are embodiments of compound (I). The present invention also encompasses embodiments in which the following embodiments are arbitrarily selected and combined.

[0035] (Embodiment 1) A compound of the present invention, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein ring A is a benzene ring or a 5- to 6-membered aromatic heterocycle. (Embodiment 2) A compound of the present invention, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein ring A is a benzene ring. (Embodiment 3) A compound of the present invention, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein ring A is a 5- to 6-membered aromatic heterocycle. (Embodiment 4) A compound of the present invention, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein ring A is a benzene ring or thiophene. (Embodiment 5) A compound of the present invention, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein ring A is thiophene.

[0036] (Embodiment 6) R １ But C １ -C ６ Alkyl group or C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 5, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a cycloalkyl group. (Embodiment 7) １ But C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 5, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 8) １ But C ３ -C ６The compound of the present invention according to any one of Embodiments 1 to 5, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a cycloalkyl group. (Embodiment 9) １ But C １ -C ４ Alkyl group or C ３ -C ４ The compound of the present invention according to any one of Embodiments 1 to 5, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a cycloalkyl group. (Embodiment 10) １ But C １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 5, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 11) １ But C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 5, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 12) １ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof according to any one of Embodiments 1 to 5, wherein is an isopropyl group.

[0037] (Embodiment 13) R ２ (Embodiment 14) The compound of the present invention according to any one of Embodiments 1 to 12, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom or a halogen atom. ２ (Embodiment 15) The compound of the present invention according to any one of Embodiments 1 to 12, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom, a fluorine atom, or a chlorine atom. ２ 13. The compound of the present invention according to any one of Embodiments 1 to 12, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein is a hydrogen atom.

[0038] (Embodiment 16) R ３ is a hydrogen atom or C １ -C ６The compound of the present invention according to any one of Embodiments 1 to 15, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 17) ３ is a hydrogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 15, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 18) ３ is a hydrogen atom or C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 15, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 19) ３ But C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 15, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 20) ３ is a hydrogen atom, a methyl group, or a CD ３ (Embodiment 21) The compound of the present invention according to any one of Embodiments 1 to 15, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a group. ３ (Embodiment 22) The compound of the present invention according to any one of Embodiments 1 to 15, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom or a methyl group. ３ (Embodiment 23) The compound of the present invention according to any one of Embodiments 1 to 15, wherein R is a hydrogen atom, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof. ３ 16. The compound of the present invention according to any one of Embodiments 1 to 15, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein

[0039] (Embodiment 24) R ４ is a hydrogen atom, a halogen atom, or C optionally substituted with 1 to 5 halogen atoms １ -C ６ C optionally substituted with an alkyl group or 1 to 5 halogen atoms １ -C ６The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 25) ４ is a halogen atom, C １ -C ６ alkyl group, or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 26) ４ is a hydrogen atom, a halogen atom, or C optionally substituted with 1 to 5 halogen atoms １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 27) ４ is a hydrogen atom, a halogen atom, or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 28) ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 29) ４ is a halogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 30) ４ is a halogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 31) ４ is a halogen atom or C １ -C ３The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 32) ４ (Embodiment 33) The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a halogen atom. ４ But C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 34) ４ (Embodiment 35) The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a halogen atom or a methyl group. ４ (Embodiment 36) The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a chlorine atom, a bromine atom, or a methyl group. ４ (Embodiment 37) The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a chlorine atom or a bromine atom. ４ (Embodiment 38) The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a methyl group. ４ (Embodiment 39) The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a halogen atom or a methoxy group. ４ (Embodiment 40) The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a chlorine atom, a bromine atom, or a methoxy group. ４ 24. The compound of the present invention according to any one of Embodiments 1 to 23, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein is a methoxy group.

[0040] (Embodiment 41) X is CR ５or a nitrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 40. (Embodiment 42) The compound of the present invention, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, ５ (Embodiment 43) The compound of the present invention according to any one of Embodiments 1 to 40, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R ５ is a hydrogen atom, a halogen atom, or C １ -C ６ alkyl group, or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 42, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 44) ５ is a hydrogen atom, a halogen atom, or C １ -C ３ alkyl group, or C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 42, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 45) ５ (Embodiment 46) The compound of the present invention according to any one of Embodiments 1 to 42, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom or a halogen atom. ５ (Embodiment 47) The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 40, wherein X is a nitrogen atom.

[0041] (Embodiment 48) G is a hydrogen atom, a formyl group, C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q1 ３ -C ６a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 is a halogen atom, a hydroxy group, a C which may be substituted with 1 to 5 substituents independently selected from Group Q3 １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, wherein G is optionally substituted by 1 to 5 substituents independently selected from the group Q1. ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group or a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from the group Q1, wherein two adjacent carbon atoms on the ring of the cycloalkyl group, the aryl group or the heteroaryl group are each substituted with a carboxy group and one hydroxy group; １ -C６ When substituted with an alkyl group, the C substituted with the carboxy group and one hydroxy group １ -C ６ The alkyl groups may be taken together with the carbon atoms to which they are attached to form a lactone ring, R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom, or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６an alkyl group, and Group Q2 is a halogen atom, a hydroxy group, an oxo group, or a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3; １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ C optionally substituted with 1 to 5 substituents independently selected from an acyl group, a carboxy group, and group Q3 １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ７ R Ｎ８ and 3- to 12-membered non-aromatic heterocyclyl groups, R Ｎ７ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ８ is a hydrogen atom or C １ -C ６ alkyl group, and the group Q3 is a halogen atom, OR Q３ , C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０ , and C ６ -C １０ is a group consisting of aryl groups, R Q３ is a hydrogen atom, C １ -C ６ C optionally substituted with an alkyl group, one amino group ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 47, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkyl group. (Embodiment 49) １ -C ４ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ４ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ The compound of the present invention according to embodiment 48, wherein G is a cycloalkyl group, a phenyl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a group represented by any of formulae (II-1) to (II-9), or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 50) １ -C ３ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ３ C optionally substituted with 1 to 3 substituents independently selected from the group Q1 ３ -C ４The compound of the present invention according to embodiment 48, wherein Group Q1 is a cycloalkyl group, a phenyl group optionally substituted with 1 to 3 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 3 substituents independently selected from Group Q1, a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 3 substituents independently selected from Group Q2, or a group represented by any of formulae (II-1) to (II-9), or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 51) The compound of the present invention according to embodiment 48, wherein Group Q1 is a halogen atom, a hydroxy group, a C optionally substituted with 1 to 5 substituents independently selected from Group Q3, １ -C ６ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 48 to 50, wherein Group Q1 is a group consisting of a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, or a pharmaceutically acceptable salt thereof. (Embodiment 52) ​​The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 48 to 50, wherein Group Q1 is a group consisting of a halogen atom, a hydroxy group, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q3, a hydroxy group, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q4, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q5, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q6, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q7, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q8, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q9, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q1, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q1, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q2, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q3, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q4, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q5, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q6, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q7, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q8, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q9, a C group １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , and P.O.R. Ｐ１ R Ｐ２ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof according to any one of Embodiments 48 to 50, wherein Group Q1 is a group consisting of: １ -C ４ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy group, carbonyl group, C １ -C ４ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , P.O.R. Ｐ１ R Ｐ２ The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 48 to 50, wherein Group Q1 is a group consisting of a halogen atom, a hydroxy group, a 3- to 12-membered non-aromatic heterocyclyl group substituted with an oxo group, and a 5- to 10-membered heteroaryl group, or a pharmaceutically acceptable salt thereof. (Embodiment 54) The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 48 to 50, wherein Group Q1 is a group consisting of a halogen atom, a hydroxy group, a 3- to 12-membered non-aromatic heterocyclyl group substituted with an oxo ... and a 5- to 10-membered heteroaryl group, or a pharmaceutically acceptable salt thereof. １ -C ４ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ４ Alkoxy group, carboxy group, C １ -C ４ Alkoxy-carbonyl group, C １ -C ４ Alkyl-SO ２ group, cyano group, NRＮ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , P.O.R. Ｐ１ R Ｐ２ The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 48 to 50, wherein Group Q1 is a group consisting of a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, or a pharmaceutically acceptable salt thereof. (Embodiment 55) The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 48 to 50, wherein Group Q1 is a group consisting of a halogen atom, a hydroxy group, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q3, a hydroxy group, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q4, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q5, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q6, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q7, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q8, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q9, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q1, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q1, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q2, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q3, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q4, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q5, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q6, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q7, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q8, a C group optionally substituted by 1 to 5 substituents independently selected from Group Q9, a C group １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ３ , R Ｎ４ , R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ The group Q3 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０ , and C ６ -C １０The compound of the present invention according to embodiment 48, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group consisting of a hydrogen atom, a C optionally substituted with 1 to 5 halogen atoms, or an aryl group. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q1 ３ -C ６ a cycloalkyl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-8): Group Q1 is a halogen atom, a hydroxy group, a C which may be substituted with 1 to 5 substituents independently selected from Group Q3 １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２ -C ６ Acyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, wherein G is optionally substituted by 1 to 5 substituents independently selected from the group Q1. ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０an aryl group or a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from the group Q1, wherein two adjacent carbon atoms on the ring of the cycloalkyl group, the aryl group or the heteroaryl group are each substituted with a carboxy group and one hydroxy group; １ -C ６ When substituted with an alkyl group, the C substituted with the carboxy group and one hydroxy group １ -C ６ The alkyl groups may be taken together with the carbon atoms to which they are attached to form a lactone ring, R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom, or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C１ -C ６ an alkyl group, and Group Q2 is a halogen atom, a hydroxy group, an oxo group, or a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3; １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ an alkoxy group, C optionally substituted with 1 to 5 substituents independently selected from the group Q3; １ -C ６ Alkoxy-carbonyl group, carboxy group, C ２ -C ６ Acyl group, cyano group, NR Ｎ７ R Ｎ８ and 3- to 12-membered non-aromatic heterocyclyl groups, R Ｎ７ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ８ is a hydrogen atom or C １ -C ６ alkyl group, and the group Q3 is a halogen atom, OR Q３ , carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０ , and C ６ -C １０ is a group consisting of aryl groups, R Q３ is a hydrogen atom, C １ -C ６ C optionally substituted with an alkyl group, one amino group ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C１ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 47, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q1 is an alkyl group. (Embodiment 57) Group Q1 is optionally substituted with 1 to 5 substituents independently selected from a halogen atom, a hydroxy group, and Group Q3. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２ -C ６ Acyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and S.O. ２ NR Ｎ５ R Ｎ６ R Ｎ３ , R Ｎ４ , R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ The group Q3 is a halogen atom, a hydroxy group, a carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０ , and C ６ -C １０ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to Embodiment 56, wherein Group Q1 is a group consisting of a halogen atom, a hydroxy group, a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3, a hydroxy group, an aryl group, or a C group optionally substituted with 1 to 5 substituents independently selected from Group Q4, a halogen atom, a hydroxy group, a C group optionally substituted with 1 to 5 substituents independently selected from Group Q5, a hydroxy group, an aryl group, a C group optionally substituted with 1 to 5 substituents independently selected from Group Q6, a hydroxy group, an aryl group, a C group optionally substituted with 1 to 5 substituents independently selected from Group Q7, a hydroxy group, an aryl group, a C group optionally substituted with 1 to 5 substituents independently selected from Group Q8, a hydroxy group, an aryl group, a C group optionally substituted with 1 to 5 substituents independently selected from Group Q9, a １ -C ６C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, wherein G is optionally substituted by 1 to 5 substituents independently selected from the group Q1. ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group or a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from the group Q1, wherein two adjacent carbon atoms on the ring of the cycloalkyl group, the aryl group or the heteroaryl group are each substituted with a carboxy group and one hydroxy group; １ -C ６ When substituted with an alkyl group, the C substituted with the carboxy group and one hydroxy group １ -C ６ The alkyl groups may be taken together with the carbon atoms to which they are attached to form a lactone ring, R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６ The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 1 to 50, or a pharmaceutically acceptable salt thereof, wherein Group Q1 is a halogen atom, a hydroxy group, or a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ , R Ｎ４ , R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６ The compound of the present invention according to embodiment 58, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkyl group. (Embodiment 60) The compound of the present invention according to embodiment 58, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a hydrogen atom, a C optionally substituted with 1 to 3 halogen atoms, １ -C ３ C optionally substituted with 1 to 3 substituents independently selected from the group Q1 ３ -C ４The compound of the present invention according to any one of Embodiments 56 to 59, wherein Group Q1 is a cycloalkyl group, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 3 substituents independently selected from Group Q1, a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 3 substituents independently selected from Group Q2, or a group represented by any of formulae (II-1) to (II-8), or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 61) The compound of the present invention according to any one of Embodiments 56 to 59, wherein Group Q1 is a halogen atom, a hydroxy group, a C optionally substituted with 1 to 5 substituents independently selected from Group Q3, a C optionally substituted with 1 to 5 substituents independently selected from Group Q4, a C optionally substituted with 1 to 5 substituents independently selected from Group Q5, a C optionally substituted with 1 to 5 substituents independently selected from Group Q6, a C optionally substituted with 1 to 5 substituents independently selected from Group Q7, a C optionally substituted with 1 to 5 substituents independently selected from Group Q8, a C optionally substituted with 1 to 5 substituents independently selected from Group Q9, a C optionally substituted with 1 to 5 substituents independently selected from Group Q1, a C optionally substituted with 1 to 5 substituents independently selected from Group Q1, a C optionally substituted with 1 to 5 substituents independently selected from Group Q2, or a C optionally substituted with 1 to 5 substituents independently selected from Group Q3, a C optionally substituted with 1 to 5 substituents independently selected from Group Q4, a C optionally substituted with 1 to 5 substituents independently selected from Group Q5, a C optionally substituted with 1 to 5 substituents independently selected from Group Q6, a C optionally substituted with 1 to 5 substituents independently selected from Group Q7, a C optionally substituted with 1 to 5 substituents independently selected from Group Q8, a C optionally substituted with 1 to １ -C ６ Alkyl group, C １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, wherein G is optionally substituted by 1 to 5 substituents independently selected from the group Q1. ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group or a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from the group Q1, wherein two adjacent carbon atoms on the ring of the cycloalkyl group, the aryl group or the heteroaryl group are each substituted with a carboxy group and one hydroxy group; １ -C ６ When substituted with an alkyl group, the C substituted with the carboxy group and one hydroxy group１ -C ６ The alkyl groups may be taken together with the carbon atoms to which they are attached to form a lactone ring, R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom, or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 1 to 50, or a pharmaceutically acceptable salt thereof, wherein Group Q1 is a halogen atom, a hydroxy group, a C optionally substituted with 1 to 5 substituents independently selected from Group Q3, and wherein Group Q4 is an alkyl group. １ -C ６ Alkyl group, C １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ , R Ｎ４ , R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６ The compound of the present invention according to Embodiment 61, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q1 is a halogen atom, a hydroxy group, or a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3.１ -C ４ Alkyl group, carboxy group, C １ -C ４ Alkyl-SO ２ group, a cyano group, and NR Ｎ１ R Ｎ２ R Ｎ１ is a hydrogen atom, and R Ｎ２ is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 50. (Embodiment 64) A compound of the present invention or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q1 is a halogen atom, C optionally substituted with one hydroxy group, １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 50, wherein Group Q1 is a C optionally substituted with a halogen atom, one hydroxy group, or a C optionally substituted with one hydroxy group. １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , and P.O.R. Ｐ１ R Ｐ２ The compound of the present invention according to any one of Embodiments 1 to 50, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, is a group consisting of: (Embodiment 66) The group Q1 is a C optionally substituted with a halogen atom, one hydroxy group, or １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 50, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 67) Ｐ１ and R Ｐ２ However, each independently, C １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 66, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 68) Ｐ１ and R Ｐ２ However, each independently, C １ -C ３ The compound of the present invention according to any one of Embodiments 48 to 66, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 69) Ｐ１ and R Ｐ２and each represent a methyl group, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 66. (Embodiment 70) The compound of the present invention, wherein Group Q1 represents a C optionally substituted with one hydroxy group, １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 69, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q1 is a group consisting of an alkyl group, a carboxy group, and an amino group. (Embodiment 71) The compound of the present invention according to any one of Embodiments 1 to 69, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q1 is a group consisting of a C optionally substituted with one hydroxy group. １ -C ４ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 69, wherein Group Q2 is a group consisting of a halogen atom, a hydroxy group, an oxo group, and Group Q3, each of which is optionally substituted with 1 to 5 substituents independently selected from a halogen atom, a hydroxy group, an oxo group, and Group Q4. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ C optionally substituted with 1 to 5 substituents independently selected from an acyl group, a carboxy group, and group Q3 １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ７ R Ｎ８ and 3- to 12-membered non-aromatic heterocyclyl groups, R Ｎ７ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ８ is a hydrogen atom or C １ -C ６The compound of the present invention or a deuterated derivative thereof according to any one of Embodiments 1 to 71, or a pharmaceutically acceptable salt thereof, wherein Group Q2 is an oxo group, a C optionally substituted with 1 to 5 substituents independently selected from Group Q3, and a C independently substituted with 1 to 5 substituents independently selected from Group Q4. １ -C ６ Alkyl group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 71, wherein Group Q2 is the group consisting of an oxo group, an alkoxy-carbonyl group, and a cyano group. (Embodiment 74) A compound of Group Q2 optionally substituted with 1 to 5 substituents independently selected from Group Q3, １ -C ６ Alkyl groups, and C ２ -C ６ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 71, wherein Group Q2 is a group consisting of an oxo group and a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 71, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q2 is a group consisting of an oxo group and one hydroxy group optionally substituted with C2. １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 71, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q2 is a group consisting of an oxo group, and C １ -C ４ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 71, wherein Group Q3 is a group consisting of alkyl groups. (Embodiment 78) The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 71, wherein Group Q3 is a group consisting of halogen atoms, hydroxy groups, C １ -C ６ Alkoxy group, C ２ -C ６Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０ , and C ６ -C １０ is a group consisting of aryl groups, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 77, wherein Group Q3 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl groups, cyano groups, and NR Ｎ９ R Ｎ１０ R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 77, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q3 is a halogen atom, OR Q３ and a carboxy group, R Q３ is a hydrogen atom, C optionally substituted with one amino group ２ -C ６ Acyl group, or C １ -C４ (Embodiment 81) The compound of the present invention or its deuterated derivative or a pharmaceutically acceptable salt thereof according to any one of Embodiments 1 to 77, wherein Group Q3 is the group consisting of a halogen atom, a hydroxy group, and a carboxy group. (Embodiment 82) The compound of the present invention or its deuterated derivative or a pharmaceutically acceptable salt thereof according to any one of Embodiments 1 to 77, wherein Group Q3 is a hydroxy group. (Embodiment 83) R Ｎ１ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 48 to 82, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 84) Ｎ１ is a hydrogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 82, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 85) Ｎ２ is a hydrogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 84, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 86) Ｎ２ The compound of the present invention according to any one of Embodiments 48 to 84, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. (Embodiment 87) Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ The compound of the present invention according to any one of Embodiments 48 to 86, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４The compound of the present invention according to any one of Embodiments 48 to 87, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 89) Ｎ４ is a hydrogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 88, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 90) Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ The compound of the present invention according to any one of Embodiments 48 to 89, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, which forms an alkylene group. (Embodiment 91) R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 90, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 92) Ｎ５ , and R Ｎ６ The compound of the present invention according to any one of Embodiments 48 to 90, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. (Embodiment 93) Ｎ９ , and R Ｎ１０ The compound of the present invention according to any one of Embodiments 48 to 92, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. (Embodiment 94) Ｎ１ is a hydrogen atom or C １ -C ３ is an alkyl group, R Ｎ２ is a hydrogen atom or C １ -C ３ is an alkyl group, R Ｎ３ is a hydrogen atom or C １ -C ３ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C３ is an alkyl group, R Ｎ５ is a hydrogen atom or C １ -C ３ is an alkyl group, R Ｎ６ is a hydrogen atom or C １ -C ６ R is an alkyl group. Ｎ７ is a hydrogen atom or C １ -C ６ R is an alkyl group. Ｎ８ is a hydrogen atom or C １ -C ６ R is an alkyl group. Ｎ９ is a hydrogen atom or C １ -C ６ R is an alkyl group. Ｎ１０ is a hydrogen atom or C １ -C ６ (Embodiment 95) The compound of the present invention according to any one of Embodiments 48 to 82, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. Ｎ１ is a hydrogen atom or a methyl group, R Ｎ２ is a hydrogen atom or a methyl group, R Ｎ３ is a hydrogen atom or a methyl group, R Ｎ４ is a hydrogen atom or a methyl group, R Ｎ５ is a hydrogen atom or a methyl group, R Ｎ６ is a hydrogen atom or a methyl group; Ｎ７ is a hydrogen atom or a methyl group; Ｎ８ is a hydrogen atom or a methyl group; Ｎ９ is a hydrogen atom or a methyl group; Ｎ１０ 83. The compound of the present invention according to any one of Embodiments 48 to 82, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein

[0042] (Embodiment 96) R Ｇ１ , R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted with 1 to 5 substituents independently selected from the group Q4１ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the group Q4 ２ -C １０ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ alkylamino-carbonyl group, and the group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C ６ R is a group consisting of 3- to 12-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ (Embodiment 97) The compound of the present invention according to any one of Embodiments 1 to 95, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. Ｇ１ , R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted with 1 to 3 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with 1 to 3 substituents independently selected from the alkyl group, group Q4 ２ -C ６ Acyl group, C １ -C ３ an alkoxy-carbonyl group, or C １ -C ３ The compound of the present invention according to embodiment 96, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkylamino-carbonyl group.Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q4 ２ -C １０ Acyl group, or C １ -C ６ The compound of the present invention according to embodiment 96 or 97, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy-carbonyl group. (Embodiment 99) Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ The compound of the present invention according to embodiment 96 or 97, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an acyl group. (Embodiment 100) Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ The compound of the present invention according to embodiment 96 or 97, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an acyl group. (Embodiment 101) Ｇ１ is a hydrogen atom or C ２ -C １０ The compound of the present invention according to embodiment 96 or 97, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an acyl group. (Embodiment 102) Ｇ１ (Embodiment 103) The compound of the present invention according to embodiment 96 or 97, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. Ｇ１ But C ２ -C １０The compound of the present invention according to embodiment 96 or 97, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an acyl group. (Embodiment 104) Ｇ１ But C ２ -C ３ The compound of the present invention according to embodiment 96 or 97, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is an acyl group. (Embodiment 105) Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ Alkyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ The compound of the present invention according to any one of Embodiments 96 to 104, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkylamino-carbonyl group. (Embodiment 106) Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ The compound of the present invention according to any one of Embodiments 96 to 104, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 107) Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The compound of the present invention according to any one of Embodiments 96 to 104, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 108) Ｇ２ is a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４The compound of the present invention according to any one of Embodiments 96 to 107, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 109) Ｇ２ The compound of the present invention according to any one of Embodiments 96 to 107, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. (Embodiment 110) Ｇ３ is a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The compound of the present invention according to any one of Embodiments 96 to 109, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 111) Ｇ３ is a hydrogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 96 to 109, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 112) Ｇ３ The compound of the present invention according to any one of Embodiments 96 to 109, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom or a methyl group. (Embodiment 113) Ｇ３ The compound of the present invention according to any one of Embodiments 96 to 109, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. (Embodiment 114) Ｇ４ is a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The compound of the present invention according to any one of Embodiments 96 to 113, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 115) Ｇ４ The compound of the present invention according to any one of Embodiments 96 to 113, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein Group Q4 is a hydroxy group, C １ -C ６The compound of the present invention or a deuterated product thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 96 to 115, wherein Group Q4 is a group consisting of a hydroxy group or a C １ -C ４ The compound of the present invention according to any one of Embodiments 96 to 115, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 118) Ｎ１１ is a hydrogen atom, C １ -C ３ Alkyl group, C ２ -C ３ Acyl group, or C １ -C ３ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ３ The compound of the present invention according to any one of Embodiments 96 to 117, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 119) Ｇ１ , R Ｇ２ , R Ｇ３ , and R Ｇ４ are each independently a hydrogen atom or C １ -C ６ alkyl group, wherein the C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 95, wherein the alkyl group is optionally substituted with 1 to 5 substituents independently selected from a halogen atom, a hydroxy group, a carboxy group, and a cyano group, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 120) R Ｇ１ , R Ｇ２ , R Ｇ３ , and R Ｇ４ are each independently a hydrogen atom or C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 95, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 121) Ｇ１ , R Ｇ２ , R Ｇ３ , and RＧ４ and R are each a hydrogen atom, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 95.

[0043] (Embodiment 122) L １ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl group, C substituted with one hydroxy group １ -C ６ C optionally substituted with an alkyl group and 1 to 5 halogen atoms １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 121, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 123) L １ But linear C １ -C ２ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ C substituted with an alkyl group and one hydroxy group １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups, wherein the linear C １ -C４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 121, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 124) L １ But 1 to 3 C １ -C ４ A linear C optionally substituted with an alkyl group １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 121, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein L is an alkylene group. (Embodiment 125) １ But linear C １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 121, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein L is an alkylene group. (Embodiment 126) １ But linear C １ -C ２ The compound of the present invention according to any one of Embodiments 1 to 121, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein L is an alkylene group. (Embodiment 127) １ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ C optionally substituted with an alkyl group and 1 to 5 halogen atoms １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C１ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 121, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 128) L １ But linear C １ -C ２ alkylene group, wherein the linear C １ -C ２ The alkylene group is selected from the group consisting of a halogen atom, a hydroxy group, and C １ -C ３ Alkyl groups, and C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 121, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups. (Embodiment 129) L １ But linear C １ -C ２ alkylene group, wherein the linear C １ -C ２ The alkylene group is 1 to 2 C １ -C ３ 122. The compound of the present invention according to any one of Embodiments 1 to 121, which may be substituted by an alkyl group, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof.

[0044] (Embodiment 130) R Ｇ５ , R Ｇ６ , R Ｇ７ , and R Ｇ１１ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６The compound of the present invention according to any one of Embodiments 1 to 129, wherein R is a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted by an alkyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 131) R Ｇ５ , R Ｇ６ , R Ｇ７ , and R Ｇ１１ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ３ Alkoxy group, carboxy group, C １ -C ３ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 129, wherein R is a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by alkyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 132) R Ｇ５ , R Ｇ６ , R Ｇ７ , and R Ｇ１１ The compound of the present invention according to any one of Embodiments 1 to 129, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, a carboxy group, or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 132, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy-carbonyl group. (Embodiment 134) Ｇ５ and R Ｇ１１ The compound of the present invention according to any one of Embodiments 1 to 132, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ５ and R Ｇ１１The compound of the present invention according to any one of Embodiments 1 to 132, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ５ The compound of the present invention according to any one of Embodiments 1 to 135, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom, a hydroxy group, or a carboxy group. (Embodiment 137) Ｇ５ The compound of the present invention according to any one of Embodiments 1 to 135, wherein R is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 138) R Ｇ１１ The compound of the present invention according to any one of Embodiments 1 to 137, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom, a hydroxy group, or a carboxy group. (Embodiment 139) Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 138, wherein R is a 4- to 6-membered non-aromatic heterocyclyl group optionally substituted by alkyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 140) R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 138, wherein R is an alkoxy-carbonyl group, a cyano group, or a 4- to 6-membered non-aromatic heterocyclyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 141) R Ｇ６ and R Ｇ７The compound of the present invention according to any one of Embodiments 1 to 138, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ６ and R Ｇ７ The compound of the present invention according to any one of Embodiments 1 to 138, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ６ The compound of the present invention according to any one of Embodiments 1 to 142, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom, a hydroxy group, or a carboxy group. (Embodiment 144) Ｇ７ The compound of the present invention according to any one of Embodiments 1 to 143, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom, a hydroxy group, or a carboxy group. (Embodiment 145) Ｇ５ , R Ｇ６ , and R Ｇ７ are each independently a hydrogen atom, a hydroxy group, a carboxy group, or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 129, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy-carbonyl group or a cyano group. (Embodiment 146) R Ｇ５ , R Ｇ６ , and R Ｇ７ are each independently a hydrogen atom, a hydroxy group, a carboxy group, or C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 129, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy-carbonyl group or a cyano group. (Embodiment 147) R Ｇ５ is a hydroxy group, a carboxy group, or C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 146, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy-carbonyl group. (Embodiment 148) R Ｇ５The compound of the present invention according to any one of Embodiments 1 to 146, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydroxy group, a carboxy group, or a methoxycarbonyl group. (Embodiment 149) Ｇ６ The compound of the present invention according to any one of Embodiments 1 to 148, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. (Embodiment 150) Ｇ７ The compound of the present invention according to any one of Embodiments 1 to 149, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a hydrogen atom. (Embodiment 151) Ｇ１１ 151. The compound of the present invention according to any one of Embodiments 1 to 150, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein is a hydrogen atom.

[0045] (Embodiment 152) L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ an alkyl group, an alkyl group substituted with one hydroxy group, a C group optionally substituted with 1 to 5 halogen atoms, １ -C ６ Alkoxy groups, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 153) L２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ an alkyl group, an alkyl group substituted with one hydroxy group, and a C group optionally substituted with 1 to 5 halogen atoms; １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 154) L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ Alkyl group, alkyl group substituted with one hydroxy group, C １ -C ６ Alkoxy groups, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C１ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 155) L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl groups, alkyl groups substituted with one hydroxy group, and C １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 156) L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl groups, alkyl groups substituted with one hydroxy group, and C ２ -C ６ acyloxy groups, wherein the linear C１ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 157) L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups. (Embodiment 158) L ２ is a single bond or a linear C １ -C ２ alkylene group, wherein the linear C １ -C ２ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ２ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups. (Embodiment 159) L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６C optionally substituted with an alkyl group and 1 to 5 halogen atoms １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, optionally forming a cycloalkane ring. (Embodiment 160) L ２ But linear C １ -C ２ alkylene group, wherein the linear C １ -C ２ The alkylene group is selected from the group consisting of a halogen atom, a hydroxy group, and C １ -C ３ Alkyl groups, and C １ -C ３ The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups. (Embodiment 161) L ２ 152. The compound of the present invention according to any one of Embodiments 1 to 151, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein is a methylene group.

[0046] (Embodiment 162) R Ｇ８ and R Ｇ９ are each independently a hydrogen atom, a halogen atom, or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group is selected from the group consisting of halogen atoms, hydroxy groups, and C １ -C ６The compound of the present invention according to any one of Embodiments 1 to 161, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, optionally substituted with 1 to 5 substituents independently selected from alkoxy groups. (Embodiment 163) R Ｇ８ and R Ｇ９ are each independently a hydrogen atom, a halogen atom, or C １ -C ３ is an alkyl group, １ -C ３ The alkyl group is selected from the group consisting of halogen atoms, hydroxy groups, and C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 161, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, optionally substituted with 1 to 3 substituents independently selected from alkoxy groups. (Embodiment 164) R Ｇ８ and R Ｇ９ The compound of the present invention according to any one of Embodiments 1 to 161, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 161, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 166) Ｇ８ and R Ｇ９ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group is a hydroxy group, and C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 161, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, optionally substituted with 1 to 5 substituents independently selected from alkoxy groups.

[0047] (Embodiment 167) R Ｇ１０ is a hydroxy group, C ２-C ６ Alkynyl group, C ２ -C ６ alkenyl group, C optionally substituted with 1 to 3 halogen atoms １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, or a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 168) Ｇ１０ is a hydroxy group, C ２ -C ６ Alkynyl group, C ２ -C ６ Alkenyl group, C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ１３ R Ｎ１４ , C１ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, or a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１４ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 169) Ｇ１０ is a hydroxy group, C ２ -C ６ an alkynyl group, C optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, or a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 170) Ｇ１０ C optionally substituted with a hydroxy group or 1 to 3 halogen atoms １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, or a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 171) Ｇ１０ is a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, C １ -C６ Alkoxy-carbonyl group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, or a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１４ is a hydrogen atom or C １ -C ６ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 172) Ｇ１０ C optionally substituted with a hydroxy group, 1 to 3 fluorine atoms １ -C ４ Alkoxy group, carboxy group, cyano group, NR Ｎ１３ R Ｎ１４ , or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 173) Ｇ１０ C optionally substituted with a hydroxy group, 1 to 3 fluorine atoms １ -C ４ Alkoxy group, carboxy group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１３ is a hydrogen atom, C ２ -C ６ Acyl group, C １ -C ４ an alkoxy-carbonyl group, or C １ -C ４ Alkyl-SO ２ It is a group R Ｎ１４ is a hydrogen atom or C １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. (Embodiment 174) Ｇ１０ C optionally substituted with a hydroxy group, 1 to 3 fluorine atoms １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ (Embodiment 175) The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ１０ is a hydroxy group, C １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ (Embodiment 176) The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ１０is a hydroxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ (Embodiment 177) The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R Ｇ１０ C optionally substituted with a hydroxy group or 1 to 3 fluorine atoms １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 178) Ｇ１０ is a hydroxy group, or C １ -C ４ The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group. (Embodiment 179) Ｇ１０ is a hydroxy group, a carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, C １ -C ６ Alkyl-SO ２ (Embodiment 180) The compound of the present invention according to any one of Embodiments 1 to 166, wherein R is a 5- to 10-membered heteroaryl group, a 5- to 10-membered heteroaryl group, or a 3- to 12-membered non-aromatic heterocyclyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. Ｇ１０ is a hydroxy group, a carboxy group, C １ -C ３ Alkoxy-carbonyl group, cyano group, C １ -C ３ Alkyl-SO ２ (Embodiment 181) The compound of the present invention according to any one of Embodiments 1 to 166, wherein R is a 5- to 6-membered heteroaryl group, a 5- to 6-membered non-aromatic heterocyclyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. Ｇ１０ is a carboxy group or C １ -C ３The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy-carbonyl group. (Embodiment 182) Ｇ１０ 167. The compound of the present invention according to any one of Embodiments 1 to 166, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein is a carboxy group or a methoxycarbonyl group.

[0048] (Embodiment 183) G is a hydrogen atom, a formyl group, C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q1 ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-2), a group represented by formula (II-3), a group represented by formula (II-4), a group represented by formula (II-5), a group represented by formula (II-6), a group represented by formula (II-7), a group represented by formula (II-8), or a group represented by formula (II-9). (Embodiment 184) １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a cycloalkyl group, a phenyl group optionally substituted with 1 to 3 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 4- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-2), a group represented by formula (II-3), a group represented by formula (II-4), a group represented by formula (II-5), a group represented by formula (II-6), a group represented by formula (II-7), a group represented by formula (II-8), or a group represented by formula (II-9), or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 185) １ -C ４ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ４ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a cycloalkyl group, a phenyl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-2), a group represented by formula (II-3), a group represented by formula (II-4), a group represented by formula (II-5), a group represented by formula (II-6), a group represented by formula (II-7), a group represented by formula (II-8), or a group represented by formula (II-9), or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 186) １ -C ４ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ４C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a cycloalkyl group, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-2), a group represented by formula (II-3), a group represented by formula (II-4), a group represented by formula (II-5), a group represented by formula (II-6), a group represented by formula (II-7), a group represented by formula (II-8), or a group represented by formula (II-9), or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 187) １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is an alkyl group, a phenyl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-3), a group represented by formula (II-5), a group represented by formula (II-6), a group represented by formula (II-8), or a group represented by formula (II-9), or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 188) １ -C ４The compound of the present invention or a deuterated version thereof according to any one of embodiments 48 to 182, or a pharmaceutically acceptable salt thereof, is an alkyl group, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-3), a group represented by formula (II-5), a group represented by formula (II-6), a group represented by formula (II-8), or a group represented by formula (II-9). (Embodiment 189) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-3), or a group represented by formula (II-8), or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 190) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a C optionally substituted with 1 to 3 halogen atoms. １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is an alkyl group, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-3), a group represented by formula (II-5), a group represented by formula (II-6), a group represented by formula (II-8), or a group represented by formula (II-9), or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 191) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a hydrogen atom, a C optionally substituted with 1 to 5 substituents independently selected from Group Q1, ３ -C ６The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a cycloalkyl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, a group represented by formula (II-1), a group represented by formula (II-2), a group represented by formula (II-3), a group represented by formula (II-4), a group represented by formula (II-5), a group represented by formula (II-6), or a group represented by formula (II-8), or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 192) ３ -C ４ The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a cycloalkyl group, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 3 substituents independently selected from Group Q1, a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 3 substituents independently selected from Group Q2, a group represented by Formula (II-1), a group represented by Formula (II-2), a group represented by Formula (II-3), a group represented by Formula (II-4), a group represented by Formula (II-5), a group represented by Formula (II-6), or a group represented by Formula (II-8), or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 193) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 194) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a formyl group, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 195) G is C １ -C ６ Alkyl-SO ２ The compound of the invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group. １ -C ４ Alkyl-SO ２The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a C optionally substituted with 1 to 5 halogen atoms. １ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkyl group. (Embodiment 198) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a C optionally substituted with 1 to 3 halogen atoms. １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkyl group. (Embodiment 199) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a C optionally substituted with 1 to 3 halogen atoms. １ -C ３ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkyl group. (Embodiment 200) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkyl group optionally substituted with 1 to 3 fluorine atoms. １ -C ４ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkyl group. (Embodiment 201) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a propyl group substituted with a fluorine atom. (Embodiment 202) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a C optionally substituted with 1 to 5 substituents independently selected from Group Q1. ３ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a cycloalkyl group. (Embodiment 203) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a C optionally substituted with 1 to 2 substituents independently selected from Group Q1. ３ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a cycloalkyl group. (Embodiment 204) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a C optionally substituted with 1 to 3 substituents independently selected from Group Q1.３ -C ４ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a cycloalkyl group. (Embodiment 205) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a hydroxycyclobutyl group. (Embodiment 206) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a hydroxycyclobutyl group. (Embodiment 207) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a hydroxycyclobutyl group. (Embodiment 208) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, ６ -C １０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an aryl group. (Embodiment 207) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a phenyl group optionally substituted with 1 to 2 substituents independently selected from Group Q1. (Embodiment 208) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a carboxy group or C １ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a phenyl group substituted with an alkoxy-carbonyl group. (Embodiment 209) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a phenyl group substituted with a carboxy group and a methyl group. (Embodiment 210) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a phenyl group substituted with a carboxy group and a halogen atom. (Embodiment 211) G is POR Ｐ１ R Ｐ２(Embodiment 212) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein G is a phenyl group substituted with (N,N-dimethylsulfamoyl)carbamoyl. (Embodiment 213) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1. (Embodiment 214) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 5- to 6-membered heteroaryl group optionally substituted with 1 to 3 substituents independently selected from Group Q1. (Embodiment 215) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 5- or 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1. (Embodiment 216) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a carboxy group or C １ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 5- or 6-membered heteroaryl group optionally substituted with an alkoxy-carbonyl group. (Embodiment 217) １ -C ３The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 5- or 6-membered heteroaryl group optionally substituted with an alkoxy-carbonyl group. (Embodiment 218) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a pyridyl group substituted with a carboxy group or a methoxycarbonyl group. (Embodiment 219) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a pyridyl group substituted with a carboxy group and a methyl group. (Embodiment 220) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a pyridyl group substituted with a carboxy group and an amino group. (Embodiment 221) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a pyridazinyl group substituted with a carboxy group or a methoxycarbonyl group. (Embodiment 222) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an oxazolyl group substituted with a carboxy group or a methoxycarbonyl group. (Embodiment 223) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an oxazolyl group substituted with a hydroxymethyl group. (Embodiment 224) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a thiadiazolyl group substituted with a 2-hydroxypropan-2-yl group. (Embodiment 225) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 5- or 6-membered heteroaryl group optionally substituted with a hydroxymethyl group. (Embodiment 226) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a pyrazyl group substituted with a hydroxymethyl group.(Embodiment 227) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a pyrimidyl group substituted by a hydroxymethyl group. (Embodiment 228) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2. (Embodiment 229) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 3 substituents independently selected from Group Q2. (Embodiment 230) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 231) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a 3- to 6-membered non-aromatic heterocyclyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 232) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is an oxetanyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 233) The compound of the present invention according to any one of Embodiments 48 to 182, wherein G is a dihydropyridazinyl group substituted with an oxo group and a 2-hydroxyethyl group, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 234) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a dihydrooxazolyl group substituted with an oxo group. (Embodiment 235) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a dihydrothiazolyl group substituted with an oxo group.(Embodiment 236) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an oxo group or a dihydrothiadiazolyl group substituted with methyl. (Embodiment 237) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-1). (Embodiment 238) G is a group represented by formula (II-1), and R. Ｇ１ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-1), and R Ｇ１ is C ２ -C ３ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an acyl group. (Embodiment 240) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-1), and R Ｇ１ is a hydrogen atom, or C ２ -C ３ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an acyl group. (Embodiment 241) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-2). (Embodiment 242) G is a group represented by formula (II-2), and R Ｇ２ is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 243) The compound of the present invention or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 182, wherein G is a group represented by formula (II-3). (Embodiment 244) G is a group represented by formula (II-3), and R Ｇ３The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-3), and R Ｇ３ is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 246) The compound of the present invention or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 182, wherein G is a group represented by formula (II-4). (Embodiment 247) G is a group represented by formula (II-4), and R Ｇ４ is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 248) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-5). (Embodiment 249) G is a group represented by formula (II-5), and L １ But one or two C １ -C ３ A straight chain C optionally substituted with an alkyl group １ -C ２ is an alkylene group, and R Ｇ５ is a hydroxy group, a carboxy group, or C １ -C ３ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkoxy-carbonyl group. (Embodiment 250) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-5), and L １ is a methylene group or an ethylene group substituted with two methyl groups, and R Ｇ５ The compound of the present invention or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 182, wherein G is a group represented by formula (II-5), and L １ is an ethylene group, and R Ｇ５is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 252) The compound of the present invention or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 182, wherein G is a group represented by formula (II-6). (Embodiment 253) G is a group represented by formula (II-6), and L １ But one or two C １ -C ３ A straight chain C optionally substituted with an alkyl group １ -C ２ is an alkylene group, and R Ｇ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-6), and L １ is an ethylene group substituted with two methyl groups, and R Ｇ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-6), and L １ is a methylene group, and R Ｇ６ is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 256) The compound of the present invention or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 182, wherein G is a group represented by formula (II-7). (Embodiment 257) G is a group represented by formula (II-7), and L １ But one or two C １ -C ３ A straight chain C optionally substituted with an alkyl group １ -C ２ is an alkylene group, and R Ｇ７ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-7), and L １is a methylene group, and R Ｇ７ is a hydrogen atom, or a deuterated form thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 259) The compound of the present invention or a deuterated form thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 182, wherein G is a group represented by formula (II-8). (Embodiment 260) G is a group represented by formula (II-8), and L ２ But one or two C １ -C ３ A straight chain C optionally substituted with an alkyl group １ -C ２ is an alkylene group, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ is a carboxy group or C １ -C ３ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkoxy-carbonyl group. (Embodiment 261) G is a group represented by formula (II-8), and L ２ is a methylene group, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ is a carboxy group or C １ -C ３ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkoxy-carbonyl group. (Embodiment 262) G is a group represented by formula (II-8), and L ２ is a methylene group, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-8), and L ２ is a methylene group, and R Ｇ８ is a hydroxymethyl group, and RＧ９ is a hydrogen atom, and R Ｇ１０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-8), and L ２ is a methylene group substituted with a trifluoromethyl group, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-8), and L ２ is a methylene group, and R Ｇ８ and R Ｇ９ are each a methyl group, and R Ｇ１０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-8), and L ２ is an ethylene group optionally substituted with one hydroxy group, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ The compound of the present invention or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 48 to 182, wherein G is a group represented by formula (II-8), and L ２ is an ethylene group substituted with one hydroxy group, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-8), and L ２ is an ethylene group substituted with one hydroxy group, and R Ｇ８and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-8), and L ２ is an ethylene group substituted with one hydroxy group and two methyl groups, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-8), and L ２ is an ethylene group, and R Ｇ８ and R Ｇ９ are each a hydrogen atom, and R Ｇ１０ C optionally substituted with 1 to 3 halogen atoms １ -C ６ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is an alkoxy group. (Embodiment 271) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-9). A hydrogenated version, or a pharmaceutically acceptable salt thereof. (Embodiment 272) The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-9). A hydrogenated version, or a pharmaceutically acceptable salt thereof. １ But one or two C １ -C ３ A straight chain C optionally substituted with an alkyl group １ -C ２ is an alkylene group, and R Ｇ１１ The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (II-9), and L １ is a methylene group, and R Ｇ１１183. The compound of the present invention according to any one of Embodiments 48 to 182, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein is a hydrogen atom.

[0049] (Embodiment 274) The compound of the present invention according to any one of Embodiments 1 to 273, wherein m and n are each independently an integer of 1 or 2, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 275) The compound of the present invention according to any one of Embodiments 1 to 273, wherein m is 1 and n is 1, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 276) The compound of the present invention according to any one of Embodiments 1 to 273, wherein m is 1 and n is 2, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 277) The compound of the present invention according to any one of Embodiments 1 to 273, wherein m is 2 and n is 1, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 278) The compound of the present invention according to any one of Embodiments 1 to 273, wherein m is 2 and n is 2, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof.

[0050] (Embodiment 279) In formula (I), ring A is a benzene ring or a 5- to 6-membered aromatic heterocycle; R １ But C １ -C ６ Alkyl group or C ３ -C ６ is a cycloalkyl group, R ２ is a hydrogen atom or a halogen atom, R ３ is a hydrogen atom or C １ -C ６ is an alkyl group, R ４ is a hydrogen atom, a halogen atom, or C optionally substituted with 1 to 5 halogen atoms １ -C ６ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom, a halogen atom, or C １ -C ６ alkyl group, or C １ -C ６an alkoxy group, and G is a hydrogen atom, a formyl group, or C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q1 ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 is a halogen atom, a hydroxy group, a C which may be substituted with 1 to 5 substituents independently selected from Group Q3 １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ , R Ｎ４ , R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６ an alkyl group, and Group Q2 is a halogen atom, a hydroxy group, an oxo group, or a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3; １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ C optionally substituted with 1 to 5 substituents independently selected from an acyl group, a carboxy group, and group Q3 １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ７ R Ｎ８ and 3- to 12-membered non-aromatic heterocyclyl groups, R Ｎ７ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ８ is a hydrogen atom or C １ -C ６ The group Q3 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０, and C ６ -C １０ is a group consisting of aryl groups, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｇ１ , R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted with 1 to 5 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the group Q4 ２ -C １０ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ alkylamino-carbonyl group, and the group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C ６ R is a group consisting of 3- to 12-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ is an alkyl group, １ But linear C １ -C ４alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl group, C substituted with one hydroxy group １ -C ６ C optionally substituted with an alkyl group and 1 to 5 halogen atoms １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ The alkyl groups together with the carbon atoms to which they are attached form C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ５ , R Ｇ６ , R Ｇ７ , and R Ｇ１１ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６ L is a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with an alkyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ an alkyl group, an alkyl group substituted with one hydroxy group, and a C group optionally substituted with 1 to 5 halogen atoms; １ -C ６and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ The alkyl groups together with the carbon atoms to which they are attached form C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ８ and R Ｇ９ are each independently a hydrogen atom, a halogen atom, or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group is selected from the group consisting of halogen atoms, hydroxy groups, and C １ -C ６ R is optionally substituted with 1 to 5 substituents independently selected from alkoxy groups; Ｇ１０ is a hydroxy group, C ２ -C ６ Alkynyl group, C ２ -C ６ Alkenyl group, C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, or a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１４ is a hydrogen atom or C １ -C ６ The compound of the present invention, or a deuterated product thereof, or a pharmaceutically acceptable salt thereof, wherein m is an alkyl group, and m and n are each independently an integer of 1 or 2.

[0051] (Embodiment 280) A compound represented by the following general formula (Ia) or (Ib): [In the formula, R １ is C １ -C ６ Alkyl group or C ３ -C ６ is a cycloalkyl group, R ２ is a hydrogen atom or a halogen atom, R ３ is a hydrogen atom or C １ -C ６ is an alkyl group, R ４ is a halogen atom, C １ -C ６ alkyl group, or C １ -C ６ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, a formyl group, C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ a cycloalkyl group, a phenyl group which may be substituted by 1 to 3 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 4- to 12-membered non-aromatic heterocyclyl group which may be substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 includes a halogen atom, a hydroxy group, and C which may be substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ６ is an alkyl group, RＮ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ are each independently C １ -C ６ Group Q2 is an oxo group, a C alkyl group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ Alkyl group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ The group Q3 is a group consisting of a halogen atom, an OR Q３ , C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl groups, cyano groups, and NR Ｎ９ R Ｎ１０ R Q３ is a hydrogen atom, C １ -C ６ C optionally substituted with an alkyl group, one amino group ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C６ is an alkyl group, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q4 ２ -C １０ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted by 1 to 2 substituents independently selected from the group Q4 １ -C ６ Alkyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C ６ R is a group consisting of 4- to 6-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ is an alkyl group, １ is a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６C substituted with an alkyl group and one hydroxy group １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, a carboxy group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６ a 4- to 6-membered non-aromatic heterocyclyl group optionally substituted with an alkyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ Alkyl group, alkyl group substituted with one hydroxy group, C １ -C ６ Alkoxy groups, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ８ and R Ｇ９ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group may be a hydroxy group, or a C １ -C ６ R is optionally substituted with 1 to 5 substituents independently selected from alkoxy groups; Ｇ１０ is a hydroxy group, C ２ -C ６ an alkynyl group, C optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, or a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ and m and n are each independently an integer of 1 or 2.] or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 278. (Embodiment 281) In formula (I-a) or (I-b), １ But C １ -C ６ Alkyl group or C ３ -C ６ is a cycloalkyl group, R ２ is a hydrogen atom or a halogen atom, R ３ is a hydrogen atom or C １ -C ６ is an alkyl group, R ４ is a halogen atom or C １ -C ６ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, a formyl group, C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ a cycloalkyl group, a phenyl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 4- to 12-membered non-aromatic heterocyclyl group which may be substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 is a halogen atom, a hydroxy group, a C which may be substituted with 1 to 5 substituents independently selected from Group Q3 １ -C ６ Alkyl group, C １ -C６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ , R Ｎ４ , R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ６ Group Q2 is an alkyl group, and Group Q3 is an oxo group, and Group Q4 is a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ Alkyl group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ The group Q3 is a group consisting of a halogen atom, a hydroxy group, a C １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １-C ６ Alkoxy-carbonyl groups, cyano groups, and NR Ｎ９ R Ｎ１０ R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q4 ２ -C １０ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ Alkyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ an alkylamino-carbonyl group; and the group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C ６ R is a group consisting of 4- to 6-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ is an alkyl group, １ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ C substituted with an alkyl group and one hydroxy group １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ The alkyl groups together with the carbon atoms to which they are attached form C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, a carboxy group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６ a 4- to 6-membered non-aromatic heterocyclyl group optionally substituted with an alkyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl groups, alkyl groups substituted with one hydroxy group, and C １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ The alkyl groups together with the carbon atoms to which they are attached form C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ６ is an alkyl group, R Ｇ１０ is a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, or a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１４is a hydrogen atom or C １ -C ６ and m and n are each independently an integer of 1 or 2.] or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, according to Embodiment 280. (Embodiment 282) In formula (I-a) or (I-b), Ｎ１ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ５ , and R Ｎ６ is a hydrogen atom; Group Q2 is an oxo group, C optionally substituted with 1 to 5 substituents independently selected from Group Q3; １ -C ６ Alkyl groups, and C ２ -C ６ R is a group consisting of acyl groups; Ｎ９ , and R Ｎ１０ is a hydrogen atom, and R Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ is an acyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ Group Q4 is a hydroxy group, C １ -C ６ R is a group consisting of an alkoxy group and an amino group; Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６an alkoxy-carbonyl group, a cyano group, or a 4- to 6-membered non-aromatic heterocyclyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl groups, alkyl groups substituted with one hydroxy group, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ The alkyl groups together with the carbon atoms to which they are attached form C ３ -C ６ A cycloalkane ring may be formed, and R Ｎ１３ is a hydrogen atom, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ (Embodiment 283) The compound of the present invention according to Embodiment 280, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a group represented by the following general formula (I-c): wherein each symbol is as defined in any one of Embodiments 1 to 278, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 284) In formula (I-c), R １ But C １ -C ６ is an alkyl group, R ４ is a hydrogen atom, a halogen atom, or C １ -C ６is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, and other symbols are as defined in any of Embodiments 1 to 278. A compound according to Embodiment 283, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 285) In formula (I-c), R １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ４ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ a cycloalkyl group, a phenyl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group which may be substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 is a halogen atom, a hydroxy group, a C which may be substituted with 1 to 5 substituents independently selected from Group Q3 １ -C ４ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ４ Alkoxy group, carboxy group, C １ -C４ Alkoxy-carbonyl group, C １ -C ４ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom, or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ４ Group Q2 is an alkyl group, and Group Q3 is an oxo group and a C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ The group Q3 is a group consisting of a halogen atom, OR Q３ and a carboxy group, R Q３is a hydrogen atom, C optionally substituted with one amino group ２ -C ６ Acyl group, or C １ -C ４ is an alkoxy-carbonyl group, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ is an acyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The group Q4 is a hydroxy group and C １ -C ４ L is a group consisting of alkoxy groups; １ But 1 to 3 C １ -C ４ A linear C optionally substituted with an alkyl group １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group;１ -C ４ is an alkyl group, R Ｇ１０ C optionally substituted with a hydroxy group, 1 to 3 fluorine atoms １ -C ４ Alkoxy group, carboxy group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１３ is a hydrogen atom, C ２ -C ６ Acyl group, C １ -C ４ an alkoxy-carbonyl group, or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ４ The compound according to embodiment 283, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is an alkyl group. １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ４ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６a cycloalkyl group, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 is a halogen atom, a hydroxy group, a C which may be substituted with 1 to 5 substituents independently selected from Group Q3 １ -C ４ Alkyl group, carboxy group, C １ -C ４ Alkyl-SO ２ group, a cyano group, and NR Ｎ１ R Ｎ２ R Ｎ１ is a hydrogen atom, and R Ｎ２ is a hydrogen atom, and Group Q2 is an oxo group and C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ The group Q3 is a group consisting of a halogen atom, a hydroxy group, and a carboxy group; R Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ is an acyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The group Q4 is a hydroxy group and C １ -C ４ L is a group consisting of alkoxy groups; １ But 1 to 3 C １ -C ４ A linear C optionally substituted with an alkyl group １ -C ４ is an alkylene group, RＧ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a hydroxy group, C １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ A compound according to Embodiment 283, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, wherein R is a group. １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom or a methoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a fluorine atom, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４an alkyl group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): Group Q1 is a C optionally substituted by a halogen atom or one hydroxy group １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom, or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ４Group Q2 is an alkyl group optionally substituted with an oxo group and one hydroxy group; １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ C optionally substituted with a hydroxy group, 1 to 3 fluorine atoms １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ 288. The compound according to embodiment 283, wherein R is a group, or a pharmaceutically acceptable salt thereof. １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４is a halogen atom, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a fluorine atom, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４ an alkyl group, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): The group Q1 is C optionally substituted with one hydroxy group １ -C ４ Q2 is a group consisting of an alkyl group, a carboxy group, and an amino group, and Q3 is a group consisting of an oxo group and a C group optionally substituted with one hydroxy group. １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a hydroxy group, C １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ 289. The compound according to embodiment 283, or a pharmaceutically acceptable salt thereof, wherein R is a group represented by the following general formula (Id): wherein each symbol is as defined in any one of embodiments 1 to 278, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof. (Embodiment 290) A compound according to any one of embodiments 1 to 278, represented by the following general formula (I-d): wherein each symbol is as defined in embodiment 287 or 288, or a pharmaceutically acceptable salt thereof. (Embodiment 291) In formula (I-d), R １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom, and R ５ is a hydrogen atom or a fluorine atom, G is a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulas (II-1), (II-3), or (II-8): The group Q1 is C optionally substituted with one hydroxy group １ -C ４ Group Q2 is a group consisting of an alkyl group and a carboxy group, and Group Q3 is a group consisting of an oxo group and a C group optionally substituted with one hydroxy group. １ -C ４ alkyl groups, R Ｇ１is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with one substituent selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a hydroxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ 292. The compound according to embodiment 290, or a pharmaceutically acceptable salt thereof, wherein R is a group. １ But C １ -C ６ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom or a methyl group, R ５ is a hydrogen atom or a fluorine atom, or a pharmaceutically acceptable salt thereof. (Embodiment 293) A compound according to embodiment 290, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I-e): wherein each symbol is as defined in embodiment 287 or 288, or a pharmaceutically acceptable salt thereof. (Embodiment 294) In formula (I-e), R １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD３ is a group, R ４ is a halogen atom or a methoxy group, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４ an alkyl group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): Group Q1 is a C optionally substituted by a halogen atom or one hydroxy group １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom, or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C３ may form an alkylene group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ４ The group Q2 is an oxo group and C １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R may be substituted with 1 to 3 substituents selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ is a hydrogen atom, and R Ｇ１０ C optionally substituted with a hydroxy group or 1 to 3 fluorine atoms １ -C ４ 295. The compound according to embodiment 293, or a pharmaceutically acceptable salt thereof, in formula (I-e), wherein R is an alkoxy group. １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４an alkyl group, a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): The group Q1 is C optionally substituted with one hydroxy group １ -C ４ The group Q2 is a group consisting of an alkyl group, a carboxy group, and an amino group, and the group Q3 is an oxo group and C １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with one substituent selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ is a hydrogen atom, and R Ｇ１０ is a hydroxy group or C １ -C ４ 296. The compound according to embodiment 293, or a pharmaceutically acceptable salt thereof, wherein R is a group selected from the group consisting of R, ... [In the formula, R １ is C １ -C ４is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, and G is a C optionally substituted with 1 to 3 halogen atoms. １ -C ４ and R is an alkyl group.] or a pharmaceutically acceptable salt thereof. (Embodiment 297) The compound according to embodiment 286, represented by the following general formula (I-c): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, and G is C optionally substituted with 1 to 2 substituents independently selected from the group Q1. ３ -C ６ Group Q1 is a cycloalkyl group optionally substituted with 1 to 5 substituents independently selected from a halogen atom, a hydroxy group, and Group Q3. １ -C ４ Alkyl group, carboxy group, C １ -C ４ Alkyl-SO ２ group, a cyano group, and NR Ｎ１ R Ｎ２ R Ｎ１ is a hydrogen atom, and R Ｎ２is a hydrogen atom, and Group Q3 is the group consisting of a halogen atom, a hydroxy group, and a carboxy group. ], or a pharmaceutically acceptable salt thereof. (Embodiment 298) The compound according to embodiment 286, represented by the following general formula (I-c): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ represents a hydrogen atom or a halogen atom, G represents a phenyl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, and Group Q1 represents a halogen atom, C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ４ Alkoxy group, carboxy group, C １ -C ４ Alkoxy-carbonyl group, C １ -C ４ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ are each independently C １ -C ４ Group Q3 is a halogen atom, OR Q３ and a carboxy group, R Q３ is a hydrogen atom, a C optionally substituted with one amino group ２ -C ６ Acyl group, or C １ -C ４ and R is an alkoxy-carbonyl group.] or a pharmaceutically acceptable salt thereof. (Embodiment 299) The compound according to embodiment 286, represented by the following general formula (I-c): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５is a hydrogen atom or a halogen atom, G is a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, and Group Q1 is a halogen atom, C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ４ Alkoxy group, carboxy group, C １ -C ４ Alkoxy-carbonyl group, C １ -C ４ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and RＰ２ are each independently C １ -C ４ Group Q3 is a halogen atom, OR Q３ and a carboxy group, R Q３ is a hydrogen atom, a C optionally substituted with one amino group ２ -C ６ Acyl group, or C １ -C ４ and R is an alkoxy-carbonyl group.] or a pharmaceutically acceptable salt thereof. (Embodiment 300) The compound according to embodiment 286, represented by the following general formula (I-c): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, and Group Q1 is a halogen atom, a hydroxy group, or C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ Alkyl group, carboxy group, C １ -C ４ Alkyl-SO ２ group, a cyano group, and NR Ｎ１ R Ｎ２ R Ｎ１ is a hydrogen atom, and R Ｎ２ is a hydrogen atom, and Group Q3 is a group consisting of a halogen atom, a hydroxy group, and a carboxy group.] or a pharmaceutically acceptable salt thereof. (Embodiment 301) The compound according to embodiment 286, represented by the following general formula (I-c): [In the formula, R １ is C１ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, and Group Q2 is an oxo group or C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ and Group Q3 is a group consisting of a halogen atom, a hydroxy group, and a carboxy group.] or a pharmaceutically acceptable salt thereof. (Embodiment 302) The compound according to embodiment 286, represented by the following general formula (I-c-1): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ Group Q4 is a hydroxy group and C １ -C ４(Embodiment 303) The compound according to embodiment 286, represented by the following general formula (I-c-1): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ Group Q4 is a hydroxy group and C １ -C ４ (Embodiment 304) The compound according to embodiment 286, represented by the following general formula (I-c-2): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, R Ｇ２ represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４The group Q4 is a hydroxy group and C １ -C ４ (Embodiment 305) The compound according to embodiment 286, represented by the following general formula (I-c-3): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, R Ｇ３ represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The group Q4 is a hydroxy group and C １ -C ４ (Embodiment 306) The compound according to embodiment 286, represented by the following general formula (I-c-4): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, R Ｇ４ represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ Group Q4 is a hydroxy group, and C１ -C ４ (Embodiment 307) The compound according to embodiment 286, represented by the following general formula (I-c-5): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, L １ is 1 to 3 C １ -C ４ A straight chain C optionally substituted with an alkyl group １ -C ４ is an alkylene group, R Ｇ５ is a hydrogen atom, a hydroxy group, or a carboxy group.] or a pharmaceutically acceptable salt thereof. (Embodiment 308) The compound according to embodiment 286, represented by the following general formula (I-c-6): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, L １ is 1 to 3 C １ -C ４ A straight chain C optionally substituted with an alkyl group １ -C ４ is an alkylene group, R Ｇ６is a hydrogen atom, a hydroxy group, or a carboxy group.] or a pharmaceutically acceptable salt thereof. (Embodiment 309) The compound according to embodiment 286, represented by the following general formula (I-c-7): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, L １ is 1 to 3 C １ -C ４ A straight chain C optionally substituted with an alkyl group １ -C ４ is an alkylene group, R Ｇ７ is a hydrogen atom, a hydroxy group, or a carboxy group.] or a pharmaceutically acceptable salt thereof. (Embodiment 310) The compound according to embodiment 286, represented by the following general formula (I-c-8): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４The alkylene group is a C substituted with a hydroxy group and 1 to 3 fluorine atoms. １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a C optionally substituted with a hydroxy group or 1 to 3 fluorine atoms. １ -C ４ Alkoxy group, carboxy group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１３ is a hydrogen atom, C ２ -C ６ Acyl group, C １ -C ４ an alkoxy-carbonyl group, or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ４ and R is an alkyl group.] or a pharmaceutically acceptable salt thereof. (Embodiment 311) The compound according to embodiment 286, represented by the following general formula (I-c-8): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, L ２is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C substituted with a hydroxy group and 1 to 3 fluorine atoms. １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a hydroxy group, C １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ (Embodiment 312) The compound according to embodiment 286, represented by the following general formula (I-c-9): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom or C １ -C ４ is an alkyl group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, L １ is 1 to 3 C １ -C ４ A straight chain C optionally substituted with an alkyl group １ -C ４ is an alkylene group, R Ｇ１１is a hydrogen atom, a hydroxy group, or a carboxy group.] or a pharmaceutically acceptable salt thereof. (Embodiment 313) A compound according to embodiment 286, represented by the following formula: (Embodiment 314) N-(2-carbamoyl-4-chlorophenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(2-carbamoyl-4-chloro-5-fluorophenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-chloro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-bromo-2-carbamoylphenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-bromo-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(2-carbamoyl-5-fluoro-4-methylphenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(5-fluoro-4-methyl-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide;2-chloro-5-(3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxyacetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N; ３-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide; 1-carbamothioyl-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N'-cyanocarbamimidoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid; methyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxetan-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(trans-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cis-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; Methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate;6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; N-(4-chloro-5-fluoro-2-((methyl-d3)carbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4,5-difluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4,5-difluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4,5-difluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((6-bromo-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-bromo-5-(3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-bromo-5-(3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-fluoro-6-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-fluoro-6-isopropylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-fluoro-6-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-ethylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-ethylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-ethylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-propylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-propylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-propylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isobutylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isobutylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isobutylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-cyclopentylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-cyclopentylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-cyclopentylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(3-isopropylthiophen-2-yl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(3-isopropylthiophen-2-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(3-isopropylthiophen-2-yl)-1-sulfamoylazetidine-3-carboxamide; 3-(5-chloro-3-isopropylthiophen-2-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-chloro-5-(3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-hydroxyacetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-hydroxypropanoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N; ３-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide; 2-chloro-5-(1-(N'-cyanocarbamimidoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid; 2-chloro-5-(1-(3-hydroxy-3-methylbutanoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-carbamothioyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)acetate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)acetic acid; ethyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)butanoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)butanoic acid;Methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoate 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoic acid; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pentanoate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pentanoic acid; Methyl 1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclobutane-1-carboxylate; 1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclobutane-1-carboxylic acid; methyl 2-(1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclopropyl)acetate; 2-(1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclopropyl)acetic acid; methyl 4-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 4-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid;Methyl 3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid; Methyl 2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid; Methyl 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)nicotinate; 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)nicotinic acid; methyl 5-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)picolinate; 5-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)picolinic acid; methyl 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)pyridazine-3-carboxylate; 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)pyridazine-3-carboxylic acid;tert-butyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutane-1-carboxylate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutane-1-carboxylic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-methylazetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(tetrahydropyran-4-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-fluoro-3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-difluoro-3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 3-hydroxypropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-hydroxypropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-hydroxyethyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,4-dihydroxybutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(tra...

Claims

1. A compound represented by the following general formula (I): wherein ring A is a benzene ring or a 5- to 6-membered aromatic heterocycle; １ is C １ -C ６ Alkyl group or C ３ -C ６ is a cycloalkyl group, R ２ is a hydrogen atom or a halogen atom, R ３ is a hydrogen atom or C １ -C ６ is an alkyl group, R ４ is a hydrogen atom, a halogen atom, or C optionally substituted with 1 to 5 halogen atoms. １ -C ６ C optionally substituted with an alkyl group or 1 to 5 halogen atoms １ -C ６ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ represents a hydrogen atom, a halogen atom, or C １ -C ６ alkyl group, or C １ -C ６ an alkoxy group, and G is a hydrogen atom, a formyl group, or C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q1 ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 includes a halogen atom, a hydroxy group, and C which may be substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , a 3- to 12-membered non-aromatic heterocyclyl group substituted by an oxo group, and a 5- to 10-membered heteroaryl group, wherein G is optionally substituted by 1 to 5 substituents independently selected from the group Q1. ３ -C ６ a cycloalkyl group, a C optionally substituted with 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group or a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from the group Q1, wherein two adjacent carbon atoms on the ring of the cycloalkyl group, the aryl group or the heteroaryl group are each substituted with a carboxy group and one hydroxy group; １ -C ６ When substituted with an alkyl group, the C substituted with the carboxy group and one hydroxy group １ -C ６ The alkyl groups may be taken together with the carbon atoms to which they are attached to form a lactone ring, R Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ are each independently C １ -C ６ Group Q2 is a C alkyl group optionally substituted with 1 to 5 substituents independently selected from a halogen atom, a hydroxy group, an oxo group, and Group Q3. １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the alkyl group, group Q3 １ -C ６ Alkoxy group, C ２ -C ６ C optionally substituted with 1 to 5 substituents independently selected from an acyl group, a carboxy group, and group Q3 １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ７ R Ｎ８ and 3- to 12-membered non-aromatic heterocyclyl groups, R Ｎ７ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ８ is a hydrogen atom or C １ -C ６ Group Q3 is a halogen atom, OR Q３ , C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, cyano group, NR Ｎ９ R Ｎ１０ , and C ６ -C １０ is a group consisting of aryl groups, R Q３ is a hydrogen atom, C １ -C ６ C optionally substituted with an alkyl group, one amino group ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｇ１ , R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted by 1 to 5 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 5 substituents independently selected from the group Q4 ２ -C １０ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ alkylamino-carbonyl group, and the group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C ６ R is a group consisting of 3- to 12-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ is an alkyl group, １ is a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl group, C substituted with one hydroxy group １ -C ６ C optionally substituted with an alkyl group and 1 to 5 halogen atoms １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ５ , R Ｇ６ , R Ｇ７ , and R Ｇ１１ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６ L is a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with an alkyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ an alkyl group, an alkyl group substituted with one hydroxy group, a C group optionally substituted with 1 to 5 halogen atoms, １ -C ６ Alkoxy groups, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ８ and R Ｇ９ are each independently a hydrogen atom, a halogen atom, or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group may be a halogen atom, a hydroxyl group, or a C １ -C ６ R is optionally substituted with 1 to 5 substituents independently selected from alkoxy groups; Ｇ１０ is a hydroxy group, C ２ -C ６ Alkynyl group, C ２ -C ６ alkenyl group, C optionally substituted with 1 to 3 halogen atoms １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 substituents independently selected from the group Q1 ６ -C １０ an aryl group, a 5- to 10-membered heteroaryl group optionally substituted with 1 to 5 substituents independently selected from Group Q1, or a 3- to 12-membered non-aromatic heterocyclyl group optionally substituted with 1 to 5 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ and m and n are each independently an integer of 1 or 2.] or a deuterated version thereof, or a pharmaceutically acceptable salt thereof.

2. A compound represented by the following general formula (I-a) or (I-b): [In the formula, R １ is C １ -C ６ Alkyl group or C ３ -C ６ is a cycloalkyl group, R ２ is a hydrogen atom or a halogen atom, R ３ is a hydrogen atom or C １ -C ６ is an alkyl group, R ４ is a halogen atom, C １ -C ６ alkyl group, or C １ -C ６ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, a formyl group, C １ -C ６ Alkyl-SO ２ group, C optionally substituted by 1 to 5 halogen atoms １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ a cycloalkyl group, a phenyl group which may be substituted by 1 to 3 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 4- to 12-membered non-aromatic heterocyclyl group which may be substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 includes a halogen atom, a hydroxy group, and C which may be substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C １ -C ６ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , S.O. ２ NR Ｎ５ R Ｎ６ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ２ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is a hydrogen atom, C １ -C ６ Alkyl group, C １ -C ６ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｎ５ , and R Ｎ６ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, R Ｐ１ and R Ｐ２ are each independently C １ -C ６ Group Q2 is an oxo group, a C alkyl group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ Alkyl group, C ２ -C ６ Acyl group, carboxy group, C １ -C ６ The group Q3 is a group consisting of a halogen atom, an OR Q３ , C ２ -C ６ Acyl group, carboxy group, C １ -C ６ Alkoxy-carbonyl groups, cyano groups, and NR Ｎ９ R Ｎ１０ R Q３ is a hydrogen atom, C １ -C ６ C optionally substituted with an alkyl group, one amino group ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ９ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１０ is a hydrogen atom or C １ -C ６ is an alkyl group, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with 1 to 2 substituents independently selected from the group Q4 ２ -C １０ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom, C optionally substituted by 1 to 2 substituents independently selected from the group Q4 １ -C ６ Alkyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Group Q4 is a halogen atom, a hydroxy group, C １ -C ６ Alkoxy group, carboxy group, cyano group, NR Ｎ１１ R Ｎ１２ , and 1 to 2 C １ -C ６ R is a group consisting of 4- to 6-membered non-aromatic heterocyclyl groups optionally substituted with alkyl groups; Ｎ１１ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｎ１２ is a hydrogen atom or C １ -C ６ is an alkyl group, １ is a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ C substituted with an alkyl group and one hydroxy group １ -C ６ and optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, a carboxy group, or C １ -C ６ is an alkoxy-carbonyl group, R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or 1 to 2 C １ -C ６ a 4- to 6-membered non-aromatic heterocyclyl group optionally substituted with an alkyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C group optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ Alkyl group, alkyl group substituted with one hydroxy group, C １ -C ６ Alkoxy groups, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ Alkyl groups, together with the carbon atom to which they are attached, form the C ３ -C ６ A cycloalkane ring may be formed, and R Ｇ８ and R Ｇ９ are each independently a hydrogen atom or C １ -C ６ is an alkyl group, １ -C ６ The alkyl group may be a hydroxy group, or a C １ -C ６ R is optionally substituted with 1 to 5 substituents independently selected from alkoxy groups; Ｇ１０ is a hydroxy group, C ２ -C ６ an alkynyl group, C optionally substituted with 1 to 3 halogen atoms; １ -C ６ Alkoxy group, carboxy group, C １ -C ６ Alkoxy-carbonyl group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , C １ -C ６ Alkyl-SO ２ group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, or a 3- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, Ｎ１３ is a hydrogen atom, C １ -C ６ Alkyl group, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ６ and m and n are each independently an integer of 1 or 2.] or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, according to claim 1, 3. R Ｎ１ is a hydrogen atom, or C １ -C ６ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ５ , and R Ｎ６ is a hydrogen atom, and Group Q2 is an oxo group, C optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ６ Alkyl groups, and C ２ -C ６ R is a group consisting of acyl groups; Ｎ９ , and R Ｎ１０ is a hydrogen atom, and R Ｇ１ C optionally substituted with a hydrogen atom, 1 to 2 substituents independently selected from the group Q4 １ -C ６ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ is an acyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ６ The group Q4 is a hydroxy group, C １ -C ６ R is a group consisting of an alkoxy group and an amino group; Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a halogen atom, a hydroxy group, or C １ -C ６ Alkoxy group, carboxy group, C １ -C ６ an alkoxy-carbonyl group, a cyano group, or a 4- to 6-membered non-aromatic heterocyclyl group; ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C, wherein the alkylene group is optionally substituted with a halogen atom, a hydroxy group, or 1 to 5 halogen atoms. １ -C ６ alkyl groups, alkyl groups substituted with one hydroxy group, and C ２ -C ６ acyloxy groups, wherein the linear C １ -C ４ Any one carbon atom of the alkylene group is two C １ -C ６ When substituted with an alkyl group, the two C １ -C ６ The alkyl groups together with the carbon atoms to which they are attached form C ３ -C ６ A cycloalkane ring may be formed, and R Ｎ１３ is a hydrogen atom, C ２ -C ６ Acyl group, C １ -C ６ an alkoxy-carbonyl group, or C １ -C ６ Alkyl-SO ２ 3. The compound according to claim 2, wherein: R is a group; or a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof.

4. The following general formula (I-c): [In the formula, R １ is C １ -C ４ is an alkyl group, R ３ is a hydrogen atom or C １ -C ４ is an alkyl group, R ４ is a halogen atom, C １ -C ４ alkyl group, or C １ -C ４ is an alkoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a halogen atom, G is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, C optionally substituted with 1 to 3 halogen atoms １ -C ４ C optionally substituted with 1 to 2 substituents independently selected from the group Q1 ３ -C ６ a cycloalkyl group, a phenyl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group which may be substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group which may be substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulae (II-1) to (II-9): Group Q1 includes a halogen atom, a hydroxy group, and C which may be substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ an alkyl group, a C group optionally substituted with 1 to 3 halogen atoms; １ -C ４ Alkoxy group, carboxy group, C １ -C ４ Alkoxy-carbonyl group, C １ -C ４ Alkyl-SO ２ group, cyano group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , P.O.R. Ｐ１ R Ｐ２ , 3- to 12-membered non-aromatic heterocyclyl groups substituted with oxo groups, and 5- to 10-membered heteroaryl groups; Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ are each independently C １ -C ４ Group Q2 is an alkyl group, and Group Q3 is an oxo group and a C group optionally substituted with 1 to 5 substituents independently selected from Group Q3. １ -C ４ Group Q3 is a group consisting of a halogen atom, OR Q３ and a carboxy group, R Q３ is a hydrogen atom, a C optionally substituted with one amino group ２ -C ６ Acyl group, or C １ -C ４ is an alkoxy-carbonyl group, R Ｇ１ is a hydrogen atom, C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ C optionally substituted with an alkyl group or 1 to 2 substituents independently selected from the group Q4 ２ -C １０ is an acyl group, R Ｇ２ , R Ｇ３ , and R Ｇ４ each independently represents a hydrogen atom or C optionally substituted with 1 to 2 substituents independently selected from the group Q4 １ -C ４ The group Q4 is a hydroxy group and C １ -C ４ L is a group consisting of alkoxy groups; １ is 1 to 3 C １ -C ４ A linear C optionally substituted with an alkyl group １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; R Ｇ６ and R Ｇ７ are each independently a hydrogen atom, a hydroxy group, or a carboxy group; L ２ is a single bond or a linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ The alkylene group is a C substituted with a hydroxy group and 1 to 3 fluorine atoms. １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a C optionally substituted with a hydroxy group or 1 to 3 fluorine atoms. １ -C ４ Alkoxy group, carboxy group, C ２ -C ６ Acyloxy group, cyano group, NR Ｎ１３ R Ｎ１４ , or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１３ is a hydrogen atom, C ２ -C ６ Acyl group, C １ -C ４ an alkoxy-carbonyl group, or C １ -C ４ Alkyl-SO ２ is a group, R Ｎ１４ is a hydrogen atom or C １ -C ４ 2. The compound according to claim 1, wherein the compound is a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof.

5. In formula (I-c), R １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom or a methoxy group, and X is CR ５ or a nitrogen atom, R ５ is a hydrogen atom or a fluorine atom, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４ an alkyl group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): Group Q1 is a C optionally substituted by a halogen atom or one hydroxy group １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ４ Group Q2 is an alkyl group optionally substituted with an oxo group and one hydroxy group; １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ C optionally substituted with a hydroxy group, 1 to 3 fluorine atoms １ -C ４ an alkoxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ The compound according to claim 4, wherein:

6. A compound represented by the following general formula (I-d):

6. The compound according to claim 5, which is represented by the formula: wherein the symbols are as defined in claim 5, or a pharmaceutically acceptable salt thereof.

7. In formula (I-d), R １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom, and R ５ is a hydrogen atom or a fluorine atom, G is a 5- to 6-membered heteroaryl group optionally substituted with 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted with 1 to 2 substituents independently selected from Group Q2, or a group represented by any of the following formulas (II-1), (II-3), or (II-8): Group Q1 is a C optionally substituted with one hydroxy group １ -C ４ Group Q2 is a group consisting of an alkyl group and a carboxy group, and Group Q3 is a group consisting of an oxo group and a C group optionally substituted with one hydroxy group. １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R is optionally substituted with one substituent selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ each independently represents a hydrogen atom or a C optionally substituted with one hydroxy group; １ -C ４ is an alkyl group, R Ｇ１０ is a hydroxy group, a carboxy group, a cyano group, or C １ -C ４ Alkyl-SO ２ The compound according to claim 6, wherein: ##STR00002## or a pharmaceutically acceptable salt thereof.

8. A compound represented by the following general formula (I-e):

6. The compound according to claim 5, which is represented by the formula: wherein the symbols are as defined in claim 5, or a pharmaceutically acceptable salt thereof.

9. In formula (I-e), R １ But C １ -C ４ is an alkyl group, R ３ is a hydrogen atom, a methyl group, or a CD ３ is a group, R ４ is a halogen atom or a methoxy group, and G is C optionally substituted with 1 to 3 halogen atoms. １ -C ４ an alkyl group, a phenyl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered heteroaryl group optionally substituted by 1 to 2 substituents independently selected from Group Q1, a 5- to 6-membered non-aromatic heterocyclyl group optionally substituted by 1 to 2 substituents independently selected from Group Q2, or a group represented by any one of the following formulas (II-1), (II-3), (II-5), (II-6), (II-8), or (II-9): Group Q1 is a C optionally substituted by a halogen atom or one hydroxy group １ -C ４ Alkyl group, carboxy group, NR Ｎ１ R Ｎ２ , C.O.R. Ｎ３ R Ｎ４ , and P.O.R. Ｐ１ R Ｐ２ R Ｎ１ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ２ is a hydrogen atom, and R Ｎ３ is a hydrogen atom, C １ -C ４ Alkyl-SO ２ group, or SO ２ NR Ｎ１５ R Ｎ１６ and R Ｎ１５ , and R Ｎ１６ are each independently a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ４ is a hydrogen atom or C １ -C ４ is an alkyl group, R Ｎ３ is SO ２ NR Ｎ１５ R Ｎ１６ When R Ｎ４ and R Ｎ１５ Together, C ２ -C ３ may form an alkylene group, R Ｐ１ and R Ｐ２ However, each independently, C １ -C ４ The group Q2 is an oxo group and C １ -C ４ alkyl groups, R Ｇ１ is a hydrogen atom or C ２ -C １０ is an acyl group, R Ｇ３ is a hydrogen atom or C １ -C ４ is an alkyl group, １ But linear C １ -C ４ is an alkylene group, R Ｇ５ and R Ｇ１１ is a hydrogen atom, and R Ｇ６ is a hydrogen atom, and L ２ But linear C １ -C ４ alkylene group, wherein the linear C １ -C ４ C in which the alkylene group is optionally substituted with a hydroxy group and 1 to 3 fluorine atoms １ -C ４ R may be substituted with 1 to 3 substituents selected from the group consisting of alkyl groups; Ｇ８ and R Ｇ９ is a hydrogen atom, and R Ｇ１０ C optionally substituted with a hydroxy group or 1 to 3 fluorine atoms １ -C ４ The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R is an alkoxy group.

10. N-(2-carbamoyl-4-chlorophenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(2-carbamoyl-4-chloro-5-fluorophenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-chloro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-bromo-2-carbamoylphenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(4-bromo-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-bromo-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(2-carbamoyl-5-fluoro-4-methylphenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; N-(5-fluoro-4-methyl-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxyacetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N; ３ -(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide; 1-carbamothioyl-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N'-cyanocarbamimidoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid; Methyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxetan-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(trans-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cis-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; N-(4-chloro-5-fluoro-2-((methyl-d3)carbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4,5-difluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4,5-difluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4,5-difluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate;N-(4-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((6-bromo-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-bromo-5-(3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-bromo-5-(3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-fluoro-6-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-fluoro-6-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-fluoro-6-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-ethylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-ethylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-ethylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-propylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-propylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-propylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isobutylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isobutylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isobutylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-cyclopentylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-cyclopentylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-cyclopentylphenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(3-isopropylthiophen-2-yl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(3-isopropylthiophen-2-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(3-isopropylthiophen-2-yl)-1-sulfamoylazetidine-3-carboxamide; 3-(5-chloro-3-isopropylthiophen-2-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-sulfamoylazetidine-3-carboxamide; tert-butyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate;2-chloro-5-(3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-hydroxyacetyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-hydroxypropanoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N; ３ -(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-1,3-dicarboxamide; 2-chloro-5-(1-(N'-cyanocarbamimidoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethyl-4-oxobutanoic acid; 2-chloro-5-(1-(3-hydroxy-3-methylbutanoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-carbamothioyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)acetate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)acetic acid; ethyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)butanoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)butanoic acid;methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoate 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2,2-dimethylbutanoic acid; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pentanoate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pentanoic acid; Methyl 1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclobutane-1-carboxylate; 1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclobutane-1-carboxylic acid; Methyl 2-(1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclopropyl)acetate; 2-(1-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)cyclopropyl)acetic acid; methyl 4-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 4-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid; Methyl 3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate; 3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid; Methyl 2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoate;2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)benzoic acid; methyl 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)nicotinate; 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)nicotinic acid; methyl 5-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)picolinate; 5-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)picolinic acid; methyl 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)pyridazine-3-carboxylate; 6-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)pyridazine-3-carboxylic acid; tert-butyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutane-1-carboxylate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutane-1-carboxylic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-methylazetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(tetrahydropyran-4-yl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-fluoro-3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-difluoro-3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 3-Hydroxypropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-Hydroxypropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-Hydroxyethyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,4-dihydroxybutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(trans-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(cis-3-hydroxycyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; ethyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-5-carboxylic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-5-methylnicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-5-methylnicotinic acid; Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)isonicotinate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)isonicotinic acid; Methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinic acid; Methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylnicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylnicotinic acid; Methyl 2-amino-6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 2-amino-6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; Methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-methylnicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-methylnicotinic acid; Methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methoxynicotinate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methoxynicotinic acid; Methyl 2-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 2-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; 2-chloro-5-(3-(2-isopropylphenyl)-1-(thiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylic acid; methyl 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylate; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylic acid; ethyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-4-carboxylic acid;Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylic acid; Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-4-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-4-carboxylic acid; Ethyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,3,4-thiadiazole-2-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide; Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-5-carboxylic acid; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxazole-5-carboxylic acid;Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-4-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-4-carboxylic acid; Ethyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylic acid; methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylate; 6-(3((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxylic acid; ethyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylate; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,2,4-thiadiazole-3-carboxylic acid;Ethyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,3,4-thiadiazole-2-carboxylate; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-cyanopyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-(6-acetylpyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-(methylsulfonyl)pyridazin-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-sulfamoylpyridazin-3-yl)azetidine-3-carboxamide; 2-chloro-5-(1-(6-chloropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-chloro-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-methyl-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(3-(2-isopropylphenyl)-1-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-(5-amino-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-methyl-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluoropicolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluoropicolinic acid; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylpicolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylpicolinate; methyl 6-chloro-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 6-chloro-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid;Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-methylpicolinate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-methylpicolinate; Methyl 3-amino-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 3-amino-5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; Methyl 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-2-carboxylate; 5-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrimidine-2-carboxylic acid; methyl 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 4-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid; tert-butyl (6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazin-3-yl)carbamate;1-(6-aminopyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxamide; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-methylpyridazine-3-carboxamide; 6-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N,N-dimethylpyridazine-3-carboxamide; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1,3,4-thiadiazole-2-carboxamide; 2-chloro-5-(1-(5-cyano-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-(hydroxymethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(5-(hydroxymethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-(1-hydroxyethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(4-(hydroxymethyl)oxazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(6-(hydroxymethyl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-(hydroxymethyl)-1,2,4-thiadiazol-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; Ethyl 2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-4-carboxylate; 2-chloro-5-(1-(4-(hydroxymethyl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; Methyl 2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)thiazole-5-carboxylate; 2-chloro-5-(1-(5-(hydroxymethyl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(hydroxymethyl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 1-(6-(aminomethyl)pyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;2-chloro-5-(1-(3-(2-hydroxypropan-2-yl)-1,2,4-thiadiazol-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(6-(2-hydroxypropan-2-yl)pyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(2-hydroxypropan-2-yl)thiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-cyanopropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cyanomethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-cyanoethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((1-cyanocyclopropyl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxyethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-methoxyethyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(3-methoxypropyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(prop-2-yn-1-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxetan-2-ylmethyl)azetidine-3-carboxamide; 1-((1,3-dioxolan-2-yl)methyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-cyano-2-hydroxyethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((3-(hydroxymethyl)oxetan-3-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-(2-(1H-tetrazol-5-yl)ethyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-((1H-tetrazol-5-yl)methyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-methoxypropyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-cyanoethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoate; 3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propanoic acid; 2-chloro-5-(1-(2-hydroxyethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(1-(3-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 5-(1-benzyl-3-(2-isopropylphenyl)azetidine-3-carboxamido)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(pyridin-4-ylmethyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(pyridin-3-ylmethyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-cyano-3-hydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(1-cyano-3-hydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-cyano-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxiran-2-ylmethyl)azetidine-3-carboxamide; 1-(3-amino-2-hydroxypropyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,3-dihydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (S)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide (S)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,3-dihydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2,2,2-trifluoroethyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-difluoroethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cis-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(trans-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3,3-difluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1,1-dioxidothiethan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-dioxide-2-thiaspiro[3.3]heptan-6-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(trans-3-(methylsulfonyl)cyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(cis-3-(methylsulfonyl)cyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-(methylsulfonyl)butyl)azetidine-3-carboxamide; 2-chloro-5-(1-(3-fluoropropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (R)-2-chloro-5-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (R)-2-chloro-5-(1-(2,3-dihydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(3-(methylsulfonyl)propyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-fluoroethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((3-(cyanomethyl)oxetan-3-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,2-dimethyl-1,3-dioxan-5-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-hydroxy-2-(hydroxymethyl)propyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-fluoropropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 3-fluoropropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(oxetan-3-ylmethyl)azetidine-3-carboxamide; Oxetan-3-ylmethyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-difluoropropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;2,2-Difluoropropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-chloro-5-(1-(3-cyanopropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 3-cyanopropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-fluoro-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3,3-difluoro-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (S)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,3-dihydroxy-3-methylbutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-(3-fluoro-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(2-hydroxy-2-methylpropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbutanoate; 3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbutanoic acid; Ethyl 2-(1-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutyl)acetate; 2-(1-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)cyclobutyl)acetic acid; Ethyl 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxetan-3-yl)acetate; 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)oxetan-3-yl)acetic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-(cyanomethyl)oxetan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)methyl)-3,3,3-trifluoropropanoic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-(methylsulfonyl)ethyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-(2-hydroxyethyl)oxetan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-hydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methoxypropan-2-yl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-cyclobutyl-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(trans-3-methoxycyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(cis-3-methoxycyclobutyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(trans-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(cis-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(tetrahydrofuran-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(tetrahydropyran-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1,1-dioxidetetrahydrothiopyran-4-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-oxaspiro[3.3]heptan-6-yl)azetidine-3-carboxamide; 1'-acetyl-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-[1,3'-biazetidine]-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1,3-dihydroxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(3-cyanooxetan-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-cyclobutyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(trans-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(cis-3-cyanocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-oxaspiro[3.3]heptan-6-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl ((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)carbamate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-(2-hydroxyethyl)sulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)—N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-(2,3-dihydroxypropyl)sulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; tert-butyl ((3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)sulfonyl)carbamate; 2-chloro-5-(3-(2-isopropylphenyl)-1-(N-methylsulfamoyl)azetidine-3-carboxamide)-N-methylisonicotinamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-propionylsulfamoyl)azetidine-3-carboxamide; 1-(N-acetylsulfamoyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-(N-butyrylsulfamoyl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-isobutyrylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-pentanoylsulfamoyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-hexanoylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-octanoylsulfamoyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(N-(2-methoxyacetyl)sulfamoyl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(N-propionylsulfamoyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(N-pentanoylsulfamoyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(N-heptanoylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;tert-butyl (2-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine)-1-sulfonamido)-2-oxoethyl)carbamate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(N-glycylsulfamoyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(methylcarbamothioyl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(methylcarbamothioyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2-hydroxyethyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; (R)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-((2,3-dihydroxypropyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 2-chloro-5-(1-((2-hydroxyethyl)carbamothioyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-propionylazetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-acetyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 5-(1-butyryl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide;2-chloro-5-(1-formyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-ethanethioyl-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(methylsulfonyl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; ethyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; Propyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-methoxy-2,2-dimethyl-3-oxopropyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-((3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)-2,2-dimethylpropanoate; (2,2-dimethyl-1,3-dioxan-5-yl)methyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-hydroxy-2-(hydroxymethyl)propyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-cyanoethyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate;3-Methoxy-2,2-dimethyl-3-oxopropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-((3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonyl)oxy)-2,2-dimethylpropanoic acid; 3-hydroxy-3-methylbutyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-Methoxyethyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 3-methoxypropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; 2-hydroxy-2-methylpropyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carboxylate; O-methyl 3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbothioate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(6-chloropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide)-N-methylisonicotinamide;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-(2-hydroxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-1-(1-(3-hydroxypropyl)-6-oxo-1,6-dihydropyridazin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; 1-(1-(2-aminoethyl)-6-oxo-1,6-dihydropyridazin-3-yl)-N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl)azetidine-3-carboxamide; tert-butyl 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-oxopyridazin-1(6H)-yl)acetate; 2-(3-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-oxopyridazin-1(6H)-yl)acetic acid; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrooxazol-2-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrooxazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrothiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydrothiazol-2-yl)azetidine-3-carboxamide; tert-butyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-oxo-4,5-dihydro-1H-imidazole-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide; tert-butyl 2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-4-oxo-4,5-dihydro-1H-imidazole-1-carboxylate; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(4-methyl-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-methyl-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(2-hydroxyethyl)-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-ethyl-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-oxo-4-(2-oxopropyl)-4,5-dihydro-1,3,4-thiadiazol-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; Ethyl (3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidine-1-carbonothioyl)carbamate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)azetidine-3-carboxamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-((methylcarbamoyl)carbamothioyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-methyl-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-((methylcarbamoyl)carbamothioyl)azetidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-(2-methyl-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)azetidine-3-carboxamide; tert-butyl 3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)pyrrolidine-1-carboxylate;N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)pyrrolidine-3-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-3-(2-isopropylphenyl)-1-sulfamoylpyrrolidine-3-carboxamide; tert-butyl 4-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-4-(2-isopropylphenyl)piperidine-1-carboxylate; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-4-(2-isopropylphenyl)piperidine-4-carboxamide; N-(4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)-4-(2-isopropylphenyl)-1-sulfamoylpiperidine-4-carboxamide; tert-butyl 4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidine-1-carboxylate; 2-chloro-5-(4-(2-isopropylphenyl)piperidine-4-carboxamide)-N-methylisonicotinamide; methyl 4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidine-1-carboxylate; methyl 4-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinate; 4-amino-6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)nicotinic acid; methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylamino)nicotinate; 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylamino)nicotinic acid;Methyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylate; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazine-2-carboxylic acid; 2-chloro-5-(3-(2-isopropylphenyl)-1-(6-(methylsulfonyl)pyridazin-3-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-(methylsulfonyl)pyridin-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(5-sulfamoylpyridin-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methylbenzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylbenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-methylbenzoic acid; methyl 3-chloro-4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 3-chloro-4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid;Methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluorobenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-fluorobenzoic acid; Methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methoxybenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-methoxybenzoic acid; Methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(trifluoromethyl)benzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(trifluoromethyl)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylsulfonyl)benzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(methylsulfonyl)benzoic acid; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(difluoromethoxy)benzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-(difluoromethoxy)benzoic acid;Methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3,5-difluorobenzoate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3,5-difluorobenzoic acid; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-oxo-1,3-dihydroisobenzofuran-5-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-(hydroxymethyl)benzoic acid; ethyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 5-(1-(4-carbamoyl-3-fluorophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamido)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-3-fluorophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-cyanophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyridazine-3-carboxamide;5-(1-(4-carbamoylphenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; methyl 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinate; 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinic acid; 6-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-fluoronicotinamide; 2-chloro-5-(1-(5-(hydroxymethyl)pyrazin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-(4-(1H-tetrazol-5-yl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; methyl 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinate; 5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)picolinic acid; 2-chloro-5-(1-(6-(hydroxymethyl)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1H-imidazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1H-imidazole-5-carboxylic acid; Methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-5-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-5-carboxylic acid; methyl 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-4-carboxylate; 2-(3-((4-chloro-5-fluoro-2-(methylcarbamoyl)phenyl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-1-methyl-1H-imidazole-4-carboxylic acid; methyl 4-(3-((6-bromo-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoate; 4-(3-((6-bromo-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)benzoic acid; methyl 4-(3-(2-isopropylphenyl)-3-((6-methoxy-2-(methylcarbamoyl)pyridin-3-yl)carbamoyl)azetidin-1-yl)benzoate; 4-(3-(2-isopropylphenyl)-3-((6-methoxy-2-(methylcarbamoyl)pyridin-3-yl)carbamoyl)azetidin-1-yl)benzoic acid;Methyl 6-(4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidin-1-yl)nicotinate; 6-(4-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-4-(2-isopropylphenyl)piperidin-1-yl)nicotinic acid; 2-chloro-5-(1-(3-ethoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(3-(trifluoromethoxy)propyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(1-(3-(difluoromethoxy)propyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3,3-difluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(cis-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(trans-3-fluorocyclobutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-((3-(methoxymethyl)oxetan-3-yl)methyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (R)-2-chloro-5-(1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (S)-2-chloro-5-(1-(2-hydroxy-3-methoxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-hydroxy-2-(1-hydroxycyclobutyl)ethyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(1-(3-(2,5-dioxopyrrolidin-1-yl)-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(3-ethoxy-2-hydroxypropyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2,3-dihydroxy-3-methylbutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-((3-hydroxytetrahydrofuran-3-yl)methyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-hydroxy-4-methoxybutyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(1,3-dimethoxypropan-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-methoxybutan-2-yl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-(methylamino)ethyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-(N-methylacetamido)ethyl)azetidine-3-carboxamido)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(2-(N-methylmethylsulfonamido)ethyl)azetidine-3-carboxamido)-N-methylisonicotinamide; methyl (2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)ethyl)(methyl)carbamate;2-chloro-5-(3-(2-isopropylphenyl)-1-(4-((methylsulfonyl)carbamoyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-((ethylsulfonyl)carbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(sulfamoylcarbamoyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-((N,N-dimethylsulfamoyl)carbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; (5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl acetate; (5-(3-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl propionate; (5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl methyl carbonate; (5-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)pyrazin-2-yl)methyl L-valinate; 2-chloro-5-(1-(2-(hydroxymethyl)pyrimidin-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(5-(hydroxymethyl)pyrimidin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(5-methyl-1,1-dioxide-1,2,5-thiadiazolidine-2-carbonyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(6-methyl-1,1-dioxide-1,2,6-thiadiazinan-2-carbonyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(3-(2-isopropylphenyl)-1-(4-(N-methylsulfamoylcarbamoyl)phenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(N,N-dimethylsulfamoyl)(methyl)carbamoyl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 6-(3-(1-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-(N,N-dimethylsulfamoyl)nicotinamide; 5-(3-(1-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-(N,N-dimethylsulfamoyl)picolinamide; 6-(3-(1-(6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-N-(N,N-dimethylsulfamoyl)pyridazine-3-carboxamide; 2-chloro-5-(1-(3-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(diethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(6-(dimethylphosphoryl)pyridin-3-yl)3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide;(R)-3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-2-hydroxypropyl acetate; (R)-1-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-3-hydroxypropan-2-yl acetate; (R)-3-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)propane-1,2-diyl diacetate; 2-chloro-5-(1-(5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-2-fluorophenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-chloro-4-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-2-methylphenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-3-methylphenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 2-chloro-5-(1-(2-(dimethylphosphoryl)pyrimidin-5-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; tert-butyl (2-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-5-(dimethylphosphoryl)pyridin-4-yl)carbamate;5-(1-(4-amino-5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 2-chloro-5-(1-(5-(dimethylphosphoryl)-4-(methylamino)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; 5-(1-(3-amino-4-(dimethylphosphoryl)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 5-(1-(6-amino-5-(dimethylphosphoryl)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-2-chloro-N-methylisonicotinamide; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoronicotinamide; methyl 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoropyridazine-3-carboxylate; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoropyridazine-3-carboxylic acid; 4-(3-((6-chloro-4-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-3-(2-isopropylphenyl)azetidin-1-yl)-6-fluoropyridazine-3-carboxamide; 2-chloro-5-(1-(4-(dimethylphosphoryl)-3-(methylamino)phenyl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide; and 2-chloro-5-(1-(5-(dimethylphosphoryl)-6-(methylamino)pyridin-2-yl)-3-(2-isopropylphenyl)azetidine-3-carboxamide)-N-methylisonicotinamide, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof, according to claim 1, selected from the group consisting of:

11. A pharmaceutical composition comprising the compound according to any one of claims 1 to 10, or a deuterated version thereof, or a pharmaceutically acceptable salt thereof.

12. The pharmaceutical composition according to claim 11 for preventing, alleviating, and / or treating a disease whose symptoms are improved by antagonizing lysophosphatidic acid receptors.

13. The pharmaceutical composition according to claim 12, wherein the disease whose symptoms are improved by antagonizing a lysophosphatidic acid receptor is pain or fibrosis.